| Policy Title |
Policy Number |
Effective Date |
| Abaloparatide (Tymlos) (PDF) |
CP.PHAR.345 |
October 1, 2025 |
| Abatacept (Orencia) (PDF) |
CP.PHAR.241 |
January 1, 2025 |
| Abemaciclib (Verzenio) (PDF) |
CP.PHAR.355 |
January 1, 2025 |
| Abiraterone (Zytiga) (PDF) |
CP.PHAR.84 |
April 1, 2025 |
| AbobotulinumtoxinA (Dysport) (PDF) |
CP.PHAR.230 |
October 1, 2025 |
| Abrocitinib (Cibinqo) (PDF) |
CP.PHAR.578 |
October 1, 2025 |
| Acalabrutinib (Calquence) (PDF) |
CP.PHAR.366 |
June 1, 2025 |
| Acoltremon (Tryptyr) (PDF) |
CP.PHAR.739 |
October 1, 2025 |
| Acoramidis (Attruby) (PDF) |
CP.PHAR.683 |
October 1, 2025 |
| Acyclovir Buccal tab (Sitavig) (PDF) |
CP.PMN.210 |
January 1, 2025 |
| Adagrasib (Krazati) (PDF) |
CP.PHAR.605 |
October 1, 2025 |
| ADAMTS13, recombinant-krhn (Adzynma) (PDF) |
CP.PHAR.635 |
April 1, 2025 |
| Adefovir (Hepsera) (PDF) |
CP.PHAR.142 |
January 1, 2025 |
| Ado-Trastuzumab Emtansine (Kadcyla) (PDF) |
CP.PHAR.229 |
July 1, 2025 |
| Aducanumab-avwa (Aduhelm) (PDF) |
CP.PHAR.468 |
July 1, 2025 |
| Afamelanotide (Scenesse) (PDF) |
CP.PHAR.444 |
April 1, 2025 |
| Afamitresgene Autoleucel (Tecelra) (PDF) |
CP.PHAR.678 |
May 1, 2025 |
| Afatinib (Gilotrif) (PDF) |
CP.PHAR.298 |
July 1, 2025 |
| Aflibercept (Eylea, Eylea HD, Opuviz, Yesafili, Ahzantive, Enzeevu, Pavblu) (PDF) |
CP.PHAR.184 |
Version effective until November 1, 2025 |
| Aflibercept (Eylea, Eylea HD, Opuviz, Yesafili, Ahzantive, Enzeevu, Pavblu) (PDF) |
CP.PHAR.184 |
November 1, 2025 |
| Agalsidase Beta (Fabrazyme) (PDF) |
CP.PHAR.158 |
Version effective until September 1, 2025 |
| Agalsidase Beta (Fabrazyme) (PDF) |
CP.PHAR.158 |
September 1, 2025 |
| Age Limit Override (Codeine, Tramadol, Hydrocodone) (PDF) |
CP.PMN.138 |
October 1, 2025 |
| Alectinib (Alecensa) (PDF) |
CP.PHAR.369 |
July 1, 2025 |
| Alemtuzumab (Lemtrada) (PDF) |
CP.PHAR.243 |
July 1, 2025 |
| Alendronate (Binosto, Fosamax plus D) (PDF) |
CP.PMN.88 |
April 1, 2025 |
| Alglucosidase Alfa (Lumizyme) (PDF) |
CP.PHAR.160 |
April 1, 2025 |
| Allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen-dsat (StrataGraft) (PDF) |
CP.PHAR.562 |
April 1, 2025 |
| Allogenic Processed Thymus Tissue-agdc (Rethymic) (PDF) |
CP.PHAR.563 |
April 1, 2025 |
| Alpelisib (Piqray) (PDF) |
CP.PHAR.430 |
Version effective until December 1, 2025 |
| Alpelisib (Piqray) (PDF) |
CP.PHAR.430 |
December 1, 2025 |
| Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) (PDF) |
CP.PHAR.94 |
April 1, 2025 |
| Amantadine ER (Gocovri,Osmolex ER) (PDF) |
CP.PMN.89 |
April 1, 2025 |
| Ambrisentan (Letairis®) (PDF) |
CP.PHAR.190 |
April 1, 2025 |
| Amifampridine (Firdapse)(PDF) |
CP.PHAR.411 |
April 1, 2025 |
| Amikacin (Arikayce)(PDF) |
CP.PHAR.401 |
October 1, 2025 |
| Amisulpride (Barhemsys) (PDF) |
CP.PMN.236 |
October 1, 2025 |
| Amivantamab-vmjw (Rybrevant) (PDF) |
CP.PHAR.544 |
October 1, 2025 |
| Anifrolumab-fnia (Saphnelo) (PDF) |
CP.PHAR.551 |
March 1, 2025 |
| Anti-Inhibitor Coagulant Complex, Human (Feiba) (PDF) |
CP.PHAR.217 |
April 1, 2025 |
| Antithrombin III (ATryn, Thrombate III) (PDF) |
CP.PHAR.564 |
April 1, 2025 |
| Antithymocyte Globulin (Atgam, Thymoglobulin) (PDF) |
CP.PHAR.506 |
January 1, 2025 |
| Apalutamide (Erleada) (PDF) |
CP.PCH.45 |
July 1, 2025 |
| Apomorphine (Apokyn) (PDF) |
CP.PHAR.488 |
October 1, 2025 |
| Aprepitant (Emend®) (PDF) |
CP.PMN.19 |
October 1, 2025 |
| Aprocitentan (Tryvio) (PDF) |
CP.PHAR.676 |
July 1, 2025 |
| Aripiprazole Long-Acting Injections (Abilify Maintena, Abilify Asimtufii, Aristada, Aristada Initio) (PDF) |
CP.PHAR.290 |
October 1, 2025 |
| Aripiprazole ODT, oral film (Opipza, Mezofy) (PDF) |
CP.PMN.300 |
August 1, 2025 |
| Armodafinil (Nuvigil) (PDF) |
CP.PMN.35 |
July 1, 2025 |
| Asciminib (Scemblix) (PDF) |
CP.PHAR.565 |
June 1, 2025 |
| Asenapine (Saphris, Secuado) (PDF) |
CP.PMN.15 |
October 1, 2025 |
| Asfotase Alfa (Strensiq) (PDF) |
CP.PHAR.328 |
January 1, 2025 |
| Aspirin-dipyridamole (Aggrenox) (PDF) |
CP.PMN.20 |
April 1, 2025 |
| AtezolizumaAtrasentan (Vanrafia)b (Tecentriq) (PDF) |
CP.PHAR.235 |
June 1, 2025 |
| Atidarsagene autotemcel (Lenmeldy) (PDF) |
CP.PHAR.602 |
August 1, 2025 |
| Atogepant (Qulipta) (PDF) |
CP.PHAR.566 |
January 1, 2025 |
| Atrasentan (Vanrafia) (PDF) |
CP.PHAR.727 |
July 1, 2025 |
| Avacincaptad pegol (Izervay) (PDF) |
CP.PHAR.641 |
May 1, 2025 |
| Avacopan (Tavneos) (PDF) |
CP.PHAR.515 |
April 1, 2025 |
| Avalglucosidase Alfa-ngpt (Nexviazyme) (PDF) |
CP.PHAR.521 |
April 1, 2025 |
| Avapritinib (Ayvakit) (PDF) |
CP.PHAR.454 |
April 1, 2025 |
| Avatrombopag (Doptelet) (PDF) |
CP.PHAR.130 |
January 1, 2025 |
| Avelumab (Bavencio) (PDF) |
CP.PHAR.333 |
April 1, 2025 |
| Avutometinib, Defactinib (Avmapki Fakzynja Co-Pack) (PDF) |
CP.PHAR.731 |
October 1, 2025 |
| Axatilimab-csfr (Niktimvo) (PDF) |
CP.PHAR.691 |
April 1, 2025 |
| Axicabtagene Ciloleucel (Yescarta) (PDF) |
CP.PHAR.362 |
June 1, 2025 |
| Axitinib (Inlyta) (PDF) |
CP.PHAR.100 |
April 1, 2025 |
| Azacitidine (Onureg, Vidaza) (PDF) |
CP.PHAR.387 |
March 1, 2025 |
| Azelaic Acid (Finacea) (PDF) |
HIM.PA.119 |
January 1, 2025 |
| Aztreonam (Cayston) (PDF) |
CP.PHAR.209 |
October 1, 2025 |
| Baclofen (Fleqsuvy, Gablofen, Lioresal, Lyvispah, Ozobax) (PDF) |
CP.PHAR.149 |
January 1, 2025 |
| Baloxavir Marboxil (Xofluza) (PDF) |
CP.PMN.185 |
August 1, 2025 |
| Bedaquiline (Sirturo) (PDF) |
CP.PMN.212 |
April 1, 2025 |
| Belantamab Mafodotin-blmf (Blenrep) (PDF) |
CP.PHAR.469 |
July 1, 2025 |
| Belatacept (Nulojix) (PDF) |
CP.PHAR.201 |
January 1, 2025 |
| Belimumab (Benlysta) (PDF) |
CP.PHAR.88 |
October 1, 2025 |
| Belinostat (Beleodaq) (PDF) |
CP.PHAR.311 |
March 1, 2025 |
| Belumosudil (Rezurock) (PDF) |
CP.PHAR.552 |
January 1, 2025 |
| Belzutifan (Welireg) (PDF) |
CP.PHAR.553 |
Version effective until September 1, 2025 |
| Belzutifan (Welireg) (PDF) |
CP.PHAR.553 |
September 1, 2025 |
| Bempedoic acid (Nexletol), bempedoic acid-ezetimibe (Nexlizet) (PDF) |
CP.PMN.237 |
April 1, 2025 |
| Bendamustine (Belrapzo, Bendeka, Treanda, Vivimusta) (PDF) |
CP.PHAR.307 |
March 1, 2025 |
| Benralizumab (Fasenra) (PDF) |
HIM.PA.SP70 |
March 1, 2025 |
| Benznidazole (PDF) |
CP.PMN.90 |
April 1, 2025 |
| Berdazimer (Zelsuvmi) (PDF) |
CP.PMN.293 |
July 1, 2025 |
| Beremagene geperpavec-svdt (Vyjuvek) (PDF) |
CP.PHAR.592 |
Version effective until December 1, 2025 |
| Beremagene geperpavec-svdt (Vyjuvek) (PDF) |
CP.PHAR.592 |
December 1, 2025 |
| Berotralstat (Orladeyo) (PDF) |
HIM.PA.169 |
October 1, 2025 |
| Betaine (Cystadane) (PDF) |
CP.PHAR.143 |
January 1, 2025 |
| Betamethasone Dipropionate Spray (Sernivo) (PDF) |
CP.PMN.182 |
January 1, 2025 |
| Betibeglogene Autotemcel (Zynteglo) (PDF) |
CP.PHAR.545 |
Version effective until December 1, 2025 |
| Betibeglogene Autotemcel (Zynteglo) (PDF) |
CP.PHAR.545 |
December 1, 2025 |
| Bevacizumab (Alymsys, Avastin, Avzivi, Jobevne, Mvasi, Vegzelma, Zirabev) (PDF) |
CP.PHAR.93 |
Version effective until September 1, 2025 |
| Bevacizumab (Alymsys, Avastin, Avzivi, Jobevne, Mvasi, Vegzelma, Zirabev) (PDF) |
CP.PHAR.93 |
September 1, 2025 |
| Bexarotene (Targretin Capsules, Gel) (PDF) |
CP.PHAR.75 |
July 1, 2025 |
| Bezlotoxumab (Zinplava) (PDF) |
CP.PHAR.300 |
April 1, 2025 |
| Bimatoprost Implant (Durysta) (PDF) |
CP.PHAR.486 |
October 1, 2025 |
| Binimetinib (Mektovi) (PDF) |
CP.PHAR.50 |
July 1, 2025 |
| Biologic and Non-biologic DMARDs (PDF) |
HIM.PA.SP60 |
October 1, 2025 |
| Birch Triterpenes (Filsuvez) (PDF) |
CP.PHAR.669 |
June 1, 2025 |
| Blinatumomab (Blincyto) (PDF) |
CP.PHAR.312 |
Version effective until December 1, 2025 |
| Blinatumomab (Blincyto) (PDF) |
CP.PHAR.312 |
December 1, 2025 |
| Bortezomib (Velcade) (PDF) |
CP.PHAR.410 |
April 1, 2025 |
| Bosentan (Tracleer®) (PDF) |
CP.PHAR.191 |
April 1, 2025 |
| Bosutinib (Bosulif) (PDF) |
CP.PHAR.105 |
July 1, 2025 |
| Brand Name Override and Non-Formulary Medications (PDF) |
HIM.PA.103 |
August 1, 2025 |
| Brentuximab Vedotin (Adcetris) (PDF) |
CP.PHAR.303 |
Version effective until December 1, 2025 |
| Brentuximab Vedotin (Adcetris) (PDF) |
CP.PHAR.303 |
December 1, 2025 |
| Brexanolone (Zulresso) (PDF) |
CP.PHAR.417 |
July 1, 2025 |
| Brexpiprazole (Rexulti) (PDF) |
CP.PMN.68 |
October 1, 2025 |
| Brexucabtagene Autoleucel (Tecartus) (PDF) |
CP.PHAR.472 |
April 1, 2025 |
| Brigatinib (Alunbrig) (PDF) |
CP.PHAR.342 |
July 1, 2025 |
| Brimonidine Tartrate (Mirvaso) (PDF) |
CP.PMN.192 |
October 1, 2025 |
| Brinzolamide/Brimonidine (Simbrinza) (PDF) |
HIM.PA.15 |
January 1, 2025 |
| Brivaracetam (Briviact) (PDF) |
CP.PMN.297 |
January 1, 2025 |
| Brolucizumab-dbll (Beovu) (PDF) |
CP.PHAR.445 |
June 1, 2025 |
| Budesonide (Eohilia, Uceris) (PDF) |
CP.PMN.294 |
July 1, 2025 |
| Budesonide (Tarpeyo) (PDF) |
CP.PHAR.572 |
April 1, 2025 |
| Bupropion/Naltrexone (Contrave) (PDF) |
CP.PCH.12 |
July 1, 2025 |
| Burosumab-twza (Crysvita) (PDF) |
CP.PHAR.11 |
Version effective until December 1, 2025 |
| Burosumab-twza (Crysvita) (PDF) |
CP.PHAR.11 |
December 1, 2025 |
| Butorphanol Nasal Spray (PDF) |
HIM.PA.46 |
July 1, 2025 |
| C1 Esterase Inhibitors (Berinert, Cinryze, Haegarda, Ruconest) (PDF) |
HIM.PA.170 |
October 1, 2025 |
| Cabazitaxel (Jevtana) (PDF) |
CP.PHAR.316 |
July 1, 2025 |
| Cabotegravir (Apretude), Cabotegravir/Rilpivirine (Cabenuva) (PDF) |
CP.PHAR.573 |
April 1, 2025 |
| Cabozantinib (Cometriq®, Cabometyx®) (PDF) |
CP.PHAR.111 |
April 1, 2025 |
| Calcifediol (Rayaldee) (PDF) |
CP.PMN.76 |
October 1, 2025 |
| Calcipotriene/Betamethasone Dipropionate Foam (Enstilar) (PDF) |
CP.PMN.181 |
January 1, 2025 |
| Canakinumab (Ilaris) (PDF) |
CP.PHAR.246 |
October 1, 2025 |
| Cannabidiol (Epidiolex) (PDF) |
CP.PMN.164 |
October 1, 2025 |
| Capecitabine (Xeloda) (PDF) |
CP.PHAR.60 |
July 1, 2025 |
| Capivasertib (Truqap) (PDF) |
CP.PHAR.663 |
April 1, 2025 |
| Caplacizumab-yhdp (Cablivi) (PDF) |
CP.PHAR.416 |
July 1, 2025 |
| Capmatinib (Tabrecta) (PDF) |
CP.PHAR.494 |
October 1, 2025 |
| CarbidopaLevodopa (Crexont, Rytary,Duopa, Dhivy), FoscarbidopaLevodopa (Vyalev) (PDF) |
CP.PMN.238 |
October 1, 2025 |
| Carfilzomib (Kyprolis) (PDF) |
CP.PHAR.309 |
March 1, 2025 |
| Carglumic acid (Carbaglu®) (PDF) |
CP.PHAR.206 |
June 1, 2025 |
| Cariprazine (Vraylar) (PDF) |
CP.PMN.91 |
October 1, 2025 |
| Casimersen (Amondys 45) (PDF) |
CP.PHAR.470 |
April 1, 2025 |
| Cemiplimab-rwlc (Libtayo) (PDF) |
CP.PHAR.397 |
January1, 2025 |
| Cenegermin-bkbj (Oxervate)(PDF) |
CP.PMN.186 |
April 1, 2025 |
| Cenobamate (Xcopri) (PDF) |
CP.PMN.231 |
April 1, 2025 |
| Ceritinib (Zykadia) (PDF) |
CP.PHAR.349 |
Version effective until September 1, 2025 |
| Ceritinib (Zykadia) (PDF) |
CP.PHAR.349 |
September 1, 2025 |
| Cerliponase alfa (Brineura) (PDF) |
CP.PHAR.338 |
October 1, 2025 |
| Cetuximab (Erbitux) (PDF) |
CP.PHAR.317 |
March 1, 2025 |
| Chenodiol (Chenodal) (PDF) |
CP.PMN.239 |
Version effective until December 1, 2025 |
| Chenodiol (Chenodal) (PDF) |
CP.PMN.239 |
December 1, 2025 |
| Chlorambucil (Leukeran) (PDF) |
CP.PHAR.554 |
January 1, 2025 |
| Chloramphenicol Sodium Succinate (PDF) |
CP.PHAR.388 |
October 1, 2025 |
| Cholic Acid (Cholbam) (PDF) |
CP.PHAR.390 |
January 1, 2025 |
| Ciclopirox (Penlac) (PDF) |
CP.PMN.24 |
April 1, 2025 |
| Ciltacabtagene Autoleucel (Carvykti) (PDF) |
CP.PHAR.533 |
July 1, 2025 |
| Cinacalcet (Sensipar) (PDF) |
CP.PHAR.61 |
Version effective until December 1, 2025 |
| Cinacalcet (Sensipar) (PDF) |
CP.PHAR.61 |
December 1, 2025 |
| Cipaglucosidase Alfa-atga + Miglustat (Pombiliti + Opfolda) (PDF) |
CP.PHAR.567 |
April 1, 2025 |
| Ciprofloxacin/Fluocinolone (Otovel) (PDF) |
CP.PMN.249 |
January 1, 2025 |
| Ciprofloxacin-Dexamethasone (Ciprodex) (PDF) |
CP.PMN.248 |
January 1, 2025 |
| Cladribine (Mavenclad) (PDF) |
CP.PHAR.422 |
October 1, 2025 |
| Clascoterone (Winlevi) (PDF) |
CP.PMN.257 |
April 1, 2025 |
| Clesrovimab-cfor (Enflonsia) (PDF) |
CP.PHAR.741 |
October 1, 2025 |
| Clobazam (Onfi) (PDF) |
CP.PMN.54 |
January 1, 2025 |
| CNS Stimulants (PDF) |
CP.PMN.92 |
June 1, 2025 |
| Cobimetinib (Cotellic) (PDF) |
CP.PHAR.380 |
July 1, 2025 |
| Colchicine (Colcrys, Lodoco) (PDF) |
CP.PMN.123 |
April 1, 2025 |
| Colesevelam (Welchol) (PDF) |
CP.PMN.250 |
January 1, 2025 |
| Collagenase Clostridium Histolyticum (Xiaflex) (PDF) |
CP.PHAR.82 |
October 1, 2025 |
| Colonoscopy Preparation Products (PDF) |
CP.PCH.43 |
January 1, 2025 |
| Compounded Medications (PDF) |
CP.PMN.280 |
Version effective until December 1, 2025 |
| Compounded Medications (PDF) |
CP.PMN.280 |
December 1, 2025 |
| Concizumab (Alhemo) (PDF) |
CP.PHAR.625 |
Version effective until September 1, 2025 |
| Concizumab (Alhemo) (PDF) |
CP.PHAR.625 |
September 1, 2025 |
| Conjugated Estrogens/Bazedoxifene (Duavee) (PDF) |
CP.PMN.258 |
April 1, 2025 |
| Continuous Glucose Monitors (PDF) |
AR.QC.PMN.214 |
Version effective until December 1, 2025 |
| Continuous Glucose Monitors (PDF) |
AR.QC.PMN.214 |
December 1, 2025 |
| Copanlisib (Aliqopa) (PDF) |
CP.PHAR.357 |
March 1, 2025 |
| Corticosteroids for Ophthalmic Injection (Dextenza, Iluvien, Ozurdex, Retisert, Xipere, Yutiq) (PDF) |
CP.PHAR.385 |
October 1, 2025 |
| Cosibelimab-Ipdl (Unloxcyt) (PDF) |
CP.PHAR.711 |
August 1, 2025 |
| Cosyntropin (Cortrosyn) (PDF) |
CP.PHAR.203 |
June 1, 2025 |
| Crinecerfont (Crenessity) (PDF) |
CP.PHAR.692 |
April 1, 2025 |
| Crisaborole (Eucrisa) (PDF) |
CP.PMN.110 |
July 1, 2025 |
| Crizanlizumab-tmca (Adakveo) (PDF) |
CP.PHAR.449 |
Version effective until December 1, 2025 |
| Crizanlizumab-tmca (Adakveo) (PDF) |
CP.PHAR.449 |
December 1, 2025 |
| Crizotinib (Xalkori) (PDF) |
CP.PHAR.90 |
July 1, 2025 |
| Crovalimab (PiaSky) (PDF) |
CP.PHAR.664 |
October 1, 2025 |
| Cyclosporine ophthalmic emulsion (Cequa, Klarity-C, Restasis, Verkazia, Vevye) (PDF) |
CP.PMN.48 |
October 1, 2025 |
| Cysteamine Ophthalmic (Cystaran, Cystadrops) (PDF) |
CP.PMN.130 |
July 1, 2025 |
| Cysteamine oral (Cystagon, Procysbi) (PDF) |
CP.PHAR.155 |
October 1, 2025 |
| Cytomegalovirus Immune Globulin (Cytogam) (PDF) |
CP.PHAR.277 |
October 1, 2025 |
| Dabrafenib (Tafinlar) (PDF) |
CP.PHAR.239 |
July 1, 2025 |
| Dacomitinib (Vizimpro) (PDF) |
CP.PHAR.399 |
January 1, 2025 |
| Dalfampridine (Ampyra) (PDF) |
CP.PHAR.248 |
July 1, 2025 |
| Dalteparin (Fragmin) (PDF) |
CP.PHAR.225 |
April 1, 2025 |
| Danicopan (ALXN2040) (PDF) |
CP.PHAR.665 |
Version effective until December 1, 2025 |
| Danicopan (ALXN2040) (PDF) |
CP.PHAR.665 |
December 1, 2025 |
| Daprodustat (Jesduvroq) (PDF) |
CP.PHAR.628 |
July 1, 2025 |
| Dapsone (Aczone Gel) (PDF) |
CP.PCH.32 |
January 1, 2025 |
| Daptomycin (Cubicin, Cubicin RF, Dapzura RT) (PDF) |
CP.PHAR.351 |
October 1, 2025 |
| Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro) (PDF) |
CP.PHAR.310 |
October 1, 2025 |
| Darbepoetin alfa (Aranesp) (PDF) |
CP.PHAR.236 |
Version effective until September 1, 2025 |
| Darbepoetin alfa (Aranesp) (PDF) |
CP.PHAR.236 |
September 1, 2025 |
| Darolutamide (Nubeqa) (PDF) |
CP.PHAR.435 |
October 1, 2025 |
| Dasabuvir-Ombitasvir-Paritaprevir-Ritonavir (Viekira Pak) (PDF) |
HIM.PA.SP61 |
January 1, 2025 |
| Dasatinib (Sprycel, Phyrago) (PDF) |
CP.PHAR.72 |
October 1, 2025 |
| Datopotamab Deruxtecan-dlnk (Datroway) (PDF) |
CP.PHAR.715 |
Version effective until November 1, 2025 |
| Datopotamab Deruxtecan-dlnk (Datroway) (PDF) |
CP.PHAR.715 |
November 1, 2025 |
| Daunorubicin/Cytarabine (Vyxeos) (PDF) |
CP.PHAR.352 |
January1, 2025 |
| DaxibotulinumtoxinA-lanm (Daxxify) (PDF) |
CP.PHAR.651 |
January 1, 2025 |
| Decitabine-Cedazuridine (Inqovi) (PDF) |
CP.PHAR.479 |
October 1, 2025 |
| Deferasirox (Exjade Jadenu) (PDF) |
CP.PHAR.145 |
Version effective until December 1, 2025 |
| Deferasirox (Exjade Jadenu) (PDF) |
CP.PHAR.145 |
December 1, 2025 |
| Deferiprone (Ferriprox) (PDF) |
CP.PHAR.147 |
Version effective until December 1, 2025 |
| Deferiprone (Ferriprox) (PDF) |
CP.PHAR.147 |
December 1, 2025 |
| Deferoxamine (Desferal) (PDF) |
CP.PHAR.146 |
Version effective until December 1, 2025 |
| Deferoxamine (Desferal) (PDF) |
CP.PHAR.146 |
December 1, 2025 |
| Deflazacort (Emflaza) (PDF) |
CP.PHAR.331 |
April 1, 2025 |
| Degarelix Acetate (Firmagon) (PDF) |
CP.PHAR.170 |
January 1, 2025 |
| Delafloxacin (Baxdela) (PDF) |
CP.PMN.115 |
October 1, 2025 |
| Delandistrogene moxeparvovec-rokl (Elevidys) (PDF) |
CP.PHAR.593 |
June 1, 2025 |
| Denileukin Diftitox-cxdl (Lymphir) (PDF) |
CP.PHAR.693 |
May 1, 2025 |
| Denosumab (Prolia, Xgeva), Denosumab-bbdz (Jubbonti, Wyost) (PDF) |
CP.PHAR.58 |
July 1, 2025 |
| Desmopressin Acetate (DDAVP, Stimate, Noctiva) (PDF) |
CP.PHAR.214 |
June 1, 2025 |
| Deutetrabenazine (Austedo, Austedo XR) (PDF) |
CP.PCH.42 |
July 1, 2025 |
| Dexrazoxane (Totect) (PDF) |
CP.PHAR.418 |
Version effective until September 1, 2025 |
| Dexrazoxane (Totect) (PDF) |
CP.PHAR.418 |
September 1, 2025 |
| Dextromethorphan-bupropion (Auvelity) (PDF) |
CP.PMN.284 |
January 1, 2025 |
| Dextromethorphan-Quinidine (Nuedexta) (PDF) |
CP.PMN.93 |
April 1, 2025 |
| Diazepam (Libervant, Valtoco) (PDF) |
CP.PMN.216 |
January 1, 2025 |
| Diazoxide Choline (Vykat XR) (PDF) |
CP.PHAR.701 |
July 1, 2025 |
| Dichlorphenamide (Keveyis) (PDF) |
CP.PMN.261 |
April 1, 2025 |
| Diclofenac (Cambia, Flector, Licart, Pennsaid, Solaraze, Zipsor, Zorvolex) (PDF) |
CP.PCH.28 |
January 1, 2025 |
| Dimethyl Fumarate (Tecfidera), Diroximel Fumarate (Vumerity), Monomethyl Fumarate (Bafiertam) (PDF) |
CP.PHAR.249 |
October 1, 2025 |
| Dipeptidyl Peptidase-4 Inhibitors (PDF) |
HIM.PA.58 |
May 1, 2025 |
| Dolasetron (Anzemet) (PDF) |
CP.PMN.141 |
October 1, 2025 |
| Donanemab-azbt (Kisunla) (PDF) |
CP.PHAR.594 |
March 1, 2025 |
| Donidalorsen (Dawnzera) |
CP.PHAR.717 |
November 1, 2025 |
| Dornase alfa (Pulmozyme) (PDF) |
CP.PHAR.212 |
October 1, 2025 |
| Dostarlimab-gxly (Jemperli) (PDF) |
CP.PHAR.540 |
Version effective until December 1, 2025 |
| Dostarlimab-gxly (Jemperli) (PDF) |
CP.PHAR.540 |
December 1, 2025 |
| Doxepin (Silenor, Prudoxin, Zonalon) |
HIM.PA.147 |
January 1, 2025 |
| Doxycycline Hyclate (Acticlate, Doryx), Doxycycline (Oracea) (PDF) |
CP.PMN.79 |
October 1, 2025 |
| Dupilumab (Dupixent) (PDF) |
HIM.PA.SP69 |
Version effective until November 1, 2025 |
| Dupilumab (Dupixent) (PDF) |
HIM.PA.SP69 |
November 1, 2025 |
| Durvalumab (Imfinzi) (PDF) |
CP.PHAR.339 |
Version effective until September 1, 2025 |
| Durvalumab (Imfinzi) (PDF) |
CP.PHAR.339 |
September 1, 2025 |
| Dutasteride (Avodart), Dutasteride/Tamsulosin (Jalyn) (PDF) |
CP.PMN.128 |
July 1, 2025 |
| Duvelisib (Copiktra) (PDF) |
CP.PHAR.400 |
January 1, 2025 |
| Ecallantide (Kalbitor) (PDF) |
CP.PHAR.177 |
October 1, 2025 |
| Eculizumab (Soliris) (PDF) |
CP.PHAR.97 |
Version effective until December 1, 2025 |
| Eculizumab (Soliris) (PDF) |
CP.PHAR.97 |
December 1, 2025 |
| Edaravone (Radicava, Radicava ORS) (PDF) |
CP.PHAR.343 |
Version effective until September 1, 2025 |
| Edaravone (Radicava, Radicava ORS) (PDF) |
CP.PHAR.343 |
September 1, 2025 |
| Efgartigimod Alfa-fcab, Efgartigimod/-Hyaluronidase-qvfc (Vyvgart, Vyvgart Hytrulo) (PDF) |
CP.PHAR.555 |
July 1, 2025 |
| Efinaconazole (Jublia) (PDF) |
CP.PMN.25 |
April 1, 2025 |
| Eflornithine (Iwilfin) (PDF) |
CP.PHAR.670 |
April 1, 2025 |
| Elacestrant (Orserdu) (PDF) |
CP.PHAR.623 |
Version effective until September 1, 2025 |
| Elacestrant (Orserdu) (PDF) |
CP.PHAR.623 |
September 1, 2025 |
| Eladocagene Exuparvovec-tneq (Kebilidi) (PDF) |
CP.PHAR.595 |
May 1, 2025 |
| Elafibranor (Iqirvo) (PDF) |
CP.PHAR.688 |
October 1, 2025 |
| Elagolix (Orilissa), elagolix-estradiol-norethindrone (Oriahnn) (PDF) |
CP.PHAR.136 |
January 1, 2025 |
| Elapegademase-lvlr (Revcovi) (PDF) |
CP.PHAR.419 |
July 1, 2025 |
| Elbasvir/Grazoprevir (Zepatier) (PDF) |
HIM.PA.SP62 |
Version effective until December 1, 2025 |
| Elbasvir/Grazoprevir (Zepatier) (PDF) |
HIM.PA.SP62 |
December 1, 2025 |
| Elexacaftor-ivacaftor-tezacaftor (Trikafta) (PDF) |
CP.PHAR.440 |
Version effective until December 1, 2025 |
| Elexacaftor-ivacaftor-tezacaftor (Trikafta) (PDF) |
CP.PHAR.440 |
December 1, 2025 |
| Eliglustat (Cerdelga) (PDF) |
CP.PHAR.153 |
July 1, 2025 |
| Elivaldogene Autotemcel (Skysona) (PDF) |
CP.PHAR.556 |
January 1, 2025 |
| Elosulfase Alfa (Vimizim) (PDF) |
CP.PHAR.162 |
July 1, 2025 |
| Elotuzumab (Empliciti) (PDF) |
CP.PHAR.308 |
March 1, 2025 |
| Elranatamab-bcmm (Elrexfio) (PDF) |
CP.PHAR.652 |
January 1, 2025 |
| Eltrombopag (Promacta®) (PDF) |
CP.PHAR.180 |
April 1, 2025 |
| Eluxadoline (Viberzi) (PDF) |
CP.PMN.170 |
January 1, 2025 |
| Emapalumab-lzsg (Gamifant) (PDF) |
CP.PHAR.402 |
October 1, 2025 |
| Emicizumab-kxwh (Hemlibra) (PDF) |
CP.PHAR.370 |
April 1, 2025 |
| Emtricitabine-tenofovir alafenamide (Descovy) (PDF) |
CP.PMN.235 |
July 1, 2025 |
| Ensartinib (Ensacove) (PDF) |
CP.PHAR.712 |
April 1, 2025 |
| Enasidenib (Idhifa) (PDF) |
CP.PHAR.363 |
January 1, 2025 |
| Encorafenib (Braftovi) (PDF) |
CP.PHAR.127 |
July 1, 2025 |
| Enfortumab Vedotin-ejfv (Padcev) (PDF) |
CP.PHAR.455 |
April 1, 2025 |
| Enfuvirtide (Fuzeon) (PDF) |
CP.PHAR.41 |
October 1, 2025 |
| Enoxaparin (Lovenox) (PDF) |
CP.PHAR.224 |
April 1, 2025 |
| Entecavir (Baraclude) (PDF) |
HIM.PA.08 |
Version effective until November 1, 2025 |
| Entecavir (Baraclude) (PDF) |
HIM.PA.08 |
November 1, 2025 |
| Entrectinib (Rozlytrek) (PDF) |
CP.PHAR.441 |
January 1, 2025 |
| Enzalutamide (Xtandi) (PDF) |
CP.PHAR.106 |
April 1, 2025 |
| Epcoritamab-bysp (Epkinly) (PDF) |
CP.PHAR.634 |
October 1, 2025 |
| Epinephrine (Epipen, Epipen Jr, Neffy, Auvi-Q) (PDF) |
CP.PCH.55 |
Version effective until December 1, 2025 |
| Epinephrine (Epipen, Epipen Jr, Neffy, Auvi-Q) (PDF) |
CP.PCH.55 |
December 1, 2025 |
| Eplontersen (Wainua) |
CP.PHAR.633 |
July 1, 2025 |
| Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) (PDF) |
CP.PHAR.237 |
Version effective until July 1, 2025 |
| Epoetin Alfa (Epogen, Procrit), Epoetin Alfa-epbx (Retacrit) (PDF) |
CP.PHAR.237 |
August 1, 2025 |
| Epoprostenol (Flolan, Veletri) (PDF) |
CP.PHAR.192 |
April 1, 2025 |
| Eptinezumab-jjmr (Vyepti) (PDF) |
HIM.PA.SP64 |
March 1, 2025 |
| Erdafitinib (Balversa) (PDF) |
CP.PHAR.423 |
October 1, 2025 |
| Erenumab-aaoe (Aimovig) (PDF) |
HIM.PA.SP65 |
January 1, 2025 |
| Eribulin Mesylate (Halaven) (PDF) |
CP.PHAR.318 |
January 1, 2025 |
| Erlotinib (Tarceva) (PDF) |
CP.PHAR.74 |
July 1, 2025 |
| Erwinia Asparaginase (Erwinaze, Rylaze) (PDF) |
CP.PHAR.301 |
April 1, 2025 |
| Esketamine (Spravato) (PDF) |
CP.PMN.199 |
July 1, 2025 |
| Estradiol Vaginal Ring (Femring) (PDF) |
CP.PMN.263 |
October 1, 2025 |
| Etelcalcetide (Parsabiv) (PDF) |
CP.PHAR.379 |
October 1, 2025 |
| Eteplirsen (Exondys 51) (PDF) |
CP.PHAR.288 |
April 1, 2025 |
| Etranacogene Dezaparvovec-drlb (Hemgenix) (PDF) |
CP.PHAR.580 |
April 1, 2025 |
| Everolimus (Afinitor, Afinitor Disperz, Zortress)(PDF) |
CP.PHAR.63 |
April 1, 2025 |
| Evinacumab-dgnb (Evkeeza) (PDF) |
HIM.PA.166 |
April 1, 2025 |
| Evolocumab (Repatha) (PDF) |
HIM.PA.156 |
June 1, 2025 |
| Exagamglogene autotemcel (Casgevy) (PDF) |
CP.PHAR.603 |
June 1, 2025 |
| Factor IX (Human, Recombinant) (PDF) |
CP.PHAR.218 |
April 1, 2025 |
| Factor IX Complex, Human (Profilnine) (PDF) |
CP.PHAR.219 |
April 1, 2025 |
| Factor VIIa, Recombinant (NovoSeven RT, SevenFact) (PDF) |
CP.PHAR.220 |
June 1, 2025 |
| Factor VIII (Human, Recombinant) (PDF) |
CP.PHAR.215 |
August 1, 2025 |
| Factor VIII/von Willebrand Factor Complex (Human – Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant – Vonvendi) (PDF) |
CP.PHAR.216 |
June 1, 2025 |
| Factor XIII A-Subunit, Recombinant (Tretten) (PDF) |
CP.PHAR.222 |
April 1, 2025 |
| Factor XIII, Human (Corifact) (PDF) |
CP.PHAR.221 |
April 1, 2025 |
| Famotidine-Ibuprofen (Duexis) (PDF) |
CP.PMN.120 |
October 1, 2025 |
| Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (PDF) |
CP.PHAR.456 |
April 1, 2025 |
| Faricimab-svoa (Vabysmo) (PDF) |
CP.PHAR.581 |
April 1, 2025 |
| Febuxostat (Uloric) (PDF) |
CP.PMN.57 |
April 1, 2025 |
| Fecal microbiota spores, live-brpk (Vowst) (PDF) |
CP.PHAR.632 |
October 1, 2025 |
| Fecal microbiota, live-jslm (Rebyota) (PDF) |
CP.PHAR.613 |
April 1, 2025 |
| Fedratinib (Inrebic) (PDF) |
CP.PHAR.442 |
January 1, 2025 |
| Fenfluramine (Fintepla) (PDF) |
CP.PMN.246 |
October 1, 2025 |
| Fentanyl IR (Abstral, Actiq, Fentora, Lazanda, Subsys) (PDF) |
CP.PMN.127 |
July 1, 2025 |
| Ferric Carboxymaltose (Injectafer) (PDF) |
CP.PHAR.234 |
April 1, 2025 |
| Ferric Derisomaltose (Monoferric) (PDF) |
CP.PHAR.480 |
July 1, 2025 |
| Ferric Maltol (Accrufer) (PDF) |
CP.PMN.213 |
January 1, 2025 |
| Ferric Pyrophosphate (Triferic, Triferic Avnu ) (PDF) |
CP.PHAR.624 |
July 1, 2025 |
| Ferumoxytol (Feraheme) (PDF) |
CP.PHAR.165 |
April 1, 2025 |
| Fezolinetant (Veozah) (PDF) |
CP.PMN.289 |
October 1, 2025 |
| Fibrinogen Concentrate [Human] (Fibryga, RiaSTAP) (PDF) |
CP.PHAR.526 |
July 1, 2025 |
| Fidanacogene Elaparvovec-dzkt (Beqvez) (PDF) |
CP.PHAR.643 |
January1, 2025 |
| Filgrastim (Neupogen, Zarxio, Granix, Nivestym, Releuko, Nypozi) (PDF) |
CP.PHAR.297 |
October 1, 2025 |
| Finerenone (Kerendia) (PDF) |
CP.PMN.266 |
January 1, 2025 |
| Fingolimod (Gilenya) (PDF) |
CP.PCH.38 |
July 1, 2025 |
| Fingolimod (Gilenya, Tascenso ODT) (PDF) |
CP.PHAR.251 |
October 1, 2025 |
| Fitusiran (Qfitlia) PDF |
CP.PHAR.706 |
Version effective until November 1, 2025 |
| Fitusiran (Qfitlia) PDF |
CP.PHAR.706 |
November 1, 2025 |
| Flibanserin (Addyi) (PDF) |
CP.PHAR.446 |
January 1, 2025 |
| Fluorouracil Cream (Tolak) (PDF) |
CP.PMN.165 |
January 1, 2025 |
| Fluticasone Propionate (Xhance) (PDF) |
CP.PMN.95 |
October 1, 2025 |
| Fondaparinux (Arixtra) (PDF) |
CP.PHAR.226 |
April 1, 2025 |
| Fosdenopterin (Nulibry) (PDF) |
CP.PHAR.471 |
Version effective until November 1, 2025 |
| Fosdenopterin (Nulibry) (PDF) |
CP.PHAR.471 |
November 1, 2025 |
| Fostamatinib (Tavalisse) (PDF) |
CP.PHAR.24 |
April 1, 2025 |
| Fostemsavir (Rukobia) (PDF) |
CP.PHAR.516 |
October 1, 2025 |
| Fremanezumab-vfrm (Ajovy)(PDF) |
HIM.PA.SP66 |
January 1, 2025 |
| Fruquintinib (Fruzaqla) (PDF) |
CP.PHAR.666 |
April 1, 2025 |
| Fulvestrant (Faslodex Injection) (PDF) |
CP.PHAR.424 |
Version effective until December 1, 2025 |
| Fulvestrant (Faslodex Injection) (PDF) |
CP.PHAR.424 |
December 1, 2025 |
| Furosemide (Furoscix) (PDF) |
CP.PHAR.608 |
April 1, 2025 |
| Futibatinib (Lytgobi) (PDF) |
CP.PHAR.604 |
April 1, 2025 |
| Gabapentin ER (Gralise, Horizant) (PDF) |
CP.PMN.240 |
Version effective until December 1, 2025 |
| Gabapentin ER (Gralise, Horizant) (PDF) |
CP.PMN.240 |
December 1, 2025 |
| Galcanezumab-gnlm (Emgality) (PDF) |
HIM.PA.SP67 |
October 1, 2025 |
| Galsulfase (Naglazyme) (PDF) |
CP.PHAR.161 |
July 1, 2025 |
| Ganaxolone (Ztalmy) (PDF) |
CP.PMN.278 |
July 1, 2025 |
| Garadacimab (Andembry) (PDF) |
CP.PHAR.673 |
October 1, 2025 |
| Gefitinib (Iressa) (PDF) |
CP.PHAR.68 |
July 1, 2025 |
| Gemtuzumab Ozogamicin (Mylotarg) (PDF) |
CP.PHAR.358 |
January1, 2025 |
| Gilteritinib (Xospata) (PDF) |
CP.PHAR.412 |
April 1, 2025 |
| Givinostat (Duvyzat) (PDF) |
CP.PHAR.644 |
October 1, 2025 |
| Givosiran (Givlaari) (PDF) |
CP.PHAR.457 |
April 1, 2025 |
| Glasdegib (Daurismo)(PDF) |
CP.PHAR.413 |
April 1, 2025 |
| Glatiramer (Copaxone, Glatopa) (PDF) |
CP.PHAR.252 |
July 1, 2025 |
| Glaucoma Agents (Omlonti, Rhopressa, Rocklatan, Vyzulta) (PDF) |
CP.PMN.286 |
April 1, 2025 |
| Glecaprevir/Pibrentasvir (Mavyret)(PDF) |
HIM.PA.SP36 |
Version effective until December 1, 2025 |
| Glecaprevir/Pibrentasvir (Mavyret)(PDF) |
HIM.PA.SP36 |
December 1, 2025 |
| Glofitamab-gxbm (Columvi) (PDF) |
CP.PHAR.636 |
October 1, 2025 |
| GLP-1 Receptor Agonists (PDF) |
AR.QC.PA.53 |
January 1, 2025 |
| Glycerol Phenylbutyrate (Ravicti) (PDF) |
CP.PHAR.207 |
April 1, 2025 |
| Golodirsen (Vyondys 53) (PDF) |
CP.PHAR.453 |
April 1, 2025 |
| Goserelin Acetate (Zoladex) (PDF) |
CP.PHAR.171 |
June 1, 2025 |
| Granisetron (Sancuso, Sustol) (PDF) |
CP.PMN.74 |
October 1, 2025 |
| Halcinonide (Halog) (PDF) |
HIM.PA.20 |
January 1, 2025 |
| Halobetasol Propionate Lotion (Bryhali, Lexette, Ultravate) (PDF) |
CP.PMN.180 |
January 1, 2025 |
| Halobetasol Propionate/Tazarotene (Duobrii) (PDF) |
CP.PMN.208 |
ctober 1, 2025 |
| Hemin (Panhematin) (PDF) |
CP.PHAR.181 |
April 1, 2025 |
| Histrelin Acetate (Vantas, Supprelin LA) (PDF) |
CP.PHAR.172 |
July 1, 2025 |
| House dust mite allergen extract (Odactra®) (PDF) |
CP.PMN.111 |
October 1, 2025 |
| Human Growth Hormone (Somapacitan, Somatropin) (PDF) |
HIM.PA.161 |
April 1, 2025 |
| Hyaluronate derivatives (PDF) |
CP.PHAR.05 |
January 1, 2025 |
| Hydroxyprogesterone Caproate (Makena) (PDF) |
CP.PHAR.14 |
July 1, 2025 |
| Hydroxyurea (Siklos, Xromi) (PDF) |
CP.PMN.193 |
Version effective until November 1, 2025 |
| Hydroxyurea (Siklos, Xromi) (PDF) |
CP.PMN.193 |
November 1, 2025 |
| Ibalizumab-uiyk (Trogarzo) (PDF) |
CP.PHAR.378 |
October 1, 2025 |
| Ibandronate Injection (Boniva) (PDF) |
CP.PHAR.189 |
October 1, 2025 |
| Ibrutinib (Imbruvica) (PDF) |
CP.PHAR.126 |
June 1, 2025 |
| Icatibant (Firazyr®) (PDF) |
CP.PHAR.178 |
October 1, 2025 |
| Icosapent ethyl (Vascepa) (PDF) |
CP.PMN.187 |
April 1, 2025 |
| Idecabtagene Vicleucel (Abecma) (PDF) |
CP.PHAR.481 |
July 1, 2025 |
| Idelalisib (Zydelig) (PDF) |
CP.PHAR.133 |
January 1, 2025 |
| Idursulfase (Elaprase) (PDF) |
CP.PHAR.156 |
July 1, 2025 |
| Iloperidone (Fanapt) (PDF) |
CP.PMN.32 |
October 1, 2025 |
| Iloprost (Ventavis®) (PDF) |
CP.PHAR.193 |
April 1, 2025 |
| Imatinib (Gleevec, Imkeldi) (PDF) |
CP.PHAR.65 |
July 1, 2025 |
| Imetelstat (Rytelo) (PDF) |
CP.PHAR.690 |
October 1, 2025 |
| Imiglucerase (Cerezyme) (PDF) |
CP.PHAR.154 |
July 1, 2025 |
| Immune Globulins (PDF) |
CP.PHAR.103 |
October 1, 2025 |
| Immune Globulins for PANS/PANDAS (PDF) |
AR.CP.PHAR.103 |
February 1, 2025 |
| Inavolisib (Itovebi) (PDF) |
CP.PHAR.702 |
January 1, 2025 |
| Inclisiran (Leqvio) (PDF) |
CP.PHAR.568 |
October 1, 2025 |
| IncobotulinumtoxinA (Xeomin) (PDF) |
CP.PHAR.231 |
October 1, 2025 |
| Inebilizumab-cdon (Uplizna) (PDF) |
CP.PHAR.458 |
Version effective until December 1, 2025 |
| Inebilizumab-cdon (Uplizna) (PDF) |
CP.PHAR.458 |
December 1, 2025 |
| Infertility and Fertility Preservation (PDF) |
CP.PHAR.131 |
January 1, 2025 |
| Inhaled asthma and COPD agents (PDF) |
HIM.PA.153 |
October 1, 2025 |
| Inotersen (Tegsedi) (PDF) |
CP.PHAR.405 |
July 1, 2025 |
| Inotuzumab Ozogamicin (Besponsa) (PDF) |
CP.PHAR.359 |
January1, 2025 |
| Insulin Delivery Systems (V-Go, Omnipod, InPen) (PDF) |
CP.PHAR.534 |
Version effective until November 1, 2025 |
| Insulin Delivery Systems (V-Go, Omnipod, InPen) (PDF) |
CP.PHAR.534 |
November 1, 2025 |
| Insulin Detemir (Levemir) (PDF) |
HIM.PA.171 |
June 1, 2025 |
| Insulin Glargine (Basaglar, Rezvoglar, Toujeo, unbranded Semglee) (PDF) |
HIM.PA.09 |
October 1, 2025 |
| Interferon Beta-1a (Avonex, Rebif) (PDF) |
CP.PHAR.255 |
July 1, 2025 |
| Interferon beta-1b (Betaseron, Extavia) (PDF) |
CP.PCH.46 |
October 1, 2025 |
| Interferon Gamma- 1b (Actimmune) (PDF) |
CP.PHAR.52 |
April 1, 2025 |
| Iobenguane I-131 (Azedra) (PDF) |
CP.PHAR.459 |
April 1, 2025 |
| Ipilimumab (Yervoy) (PDF) |
CP.PHAR.319 |
Version effective until September 1, 2025 |
| Ipilimumab (Yervoy) (PDF) |
CP.PHAR.319 |
October 1, 2025 |
| Iptacopan (Fabhalta) (PDF) |
CP.PHAR.656 |
Version effective until December 1, 2025 |
| Iptacopan (Fabhalta) (PDF) |
CP.PHAR.656 |
December 1, 2025 |
| Irinotecan Liposome (Onivyde) (PDF) |
CP.PHAR.304 |
January1, 2025 |
| Isatuximab-irfc (Sarclisa) (PDF) |
CP.PHAR.482 |
July 1, 2025 |
| Isavuconazonium (Cresemba) (PDF) |
CP.PMN.154 |
July 1, 2025 |
| Isotretinoin (Claravis Absorica Absorica LD Myorisan Zenatane Amnesteem) (PDF) |
CP.PMN.143 |
March 1, 2025 |
| Istradefylline (Nourianz) (PDF) |
CP.PMN.217 |
April 1, 2025 |
| Itraconazole (Sporanox, Onmel) (PDF) |
CP.PMN.124 |
July 1, 2025 |
| Ivabradine (Corlanor) (PDF) |
CP.PMN.70 |
June 1, 2025 |
| Ivacaftor (Kalydeco) (PDF) |
CP.PHAR.210 |
Version effective until December 1, 2025 |
| Ivacaftor (Kalydeco) (PDF) |
CP.PHAR.210 |
December 1, 2025 |
| Ivermectin (Stromectol, Sklice) (PDF) |
CP.PMN.269 |
October 1, 2025 |
| Ivosidenib (Tibsovo) (PDF) |
CP.PHAR.137 |
January 1, 2025 |
| Ixazomib (Ninlaro) (PDF) |
CP.PHAR.302 |
Version effective until December 1, 2025 |
| Ixazomib (Ninlaro) (PDF) |
CP.PHAR.302 |
December 1, 2025 |
| Ketamine (Ketalar) (PDF) |
CP.PMN.296 |
October 1, 2025 |
| Ketorolac nasal spray (Sprix) (PDF) |
CP.PMN.282 |
January 1, 2025 |
| Lanadelumab-fylo (Takhzyro) (PDF) |
HIM.PA.172 |
October 1, 2025 |
| Lanreotide (Somatuline Depot and Unbranded) (PDF) |
CP.PHAR.391 |
January1, 2025 |
| Lapatinib (Tykerb®) (PDF) |
CP.PHAR.79 |
January 1, 2025 |
| Laronidase (Aldurazyme) (PDF) |
CP.PHAR.152 |
July 1, 2025 |
| Larotrectinib (Vitrakvi)(PDF) |
CP.PHAR.414 |
October 1, 2025 |
| Lasmiditan (Reyvow) (PDF) |
CP.PMN.218 |
June 1, 2025 |
| Lazertinib (Lazcluze) (PDF) |
CP.PHAR.695 |
January 1, 2025 |
| Lebrikizumab (Ebglyss) (PDF) |
CP.PHAR.704 |
January 1, 2025 |
| Lecanemab-irmb (Leqembi) (PDF) |
CP.PHAR.596 |
July 1, 2025 |
| Ledipasvir-Sofosbuvir (Harvoni) (PDF) |
HIM.PA.SP3 |
Version effective until December 1, 2025 |
| Ledipasvir-Sofosbuvir (Harvoni) (PDF) |
HIM.PA.SP3 |
December 1, 2025 |
| Lefamulin (Xenleta) (PDF) |
CP.PMN.219 |
October 1, 2025 |
| Lenacapavir (Sunlenca) (PDF) |
CP.PHAR.622 |
Version effective until November 1, 2025 |
| Lenacapavir (Sunlenca) (PDF) |
CP.PHAR.622 |
November 1, 2025 |
| Lenalidomide (Revlimid) (PDF) |
CP.PHAR.71 |
Version effective until September 1, 2025 |
| Lenalidomide (Revlimid) (PDF) |
CP.PHAR.71 |
September 1, 2025 |
| Leniolisib (Joenja) (PDF) |
CP.PHAR.597 |
January 1, 2025 |
| Lenvatinib (Lenvima) (PDF) |
CP.PHAR.138 |
May 1, 2025 |
| Letermovir (Prevymis) (PDF) |
CP.PHAR.367 |
October 1, 2025 |
| Leucovorin Injection (PDF) |
CP.PHAR.393 |
May 1, 2024 |
| Leuprolide Acetate (Eligard, Fensolvi, Lupaneta Pack, Lupron Depot, Lupron Depot-Ped), Leuprolide mesylate (Camcevi) (PDF) |
CP.PHAR.173 |
May 1, 2024 |
| Leuprolide Acetate (Lupron, Eligard, Lupaneta Pack, Fensolvi, Camcevi) (PDF) |
CP.PCH.53 |
June 1, 2025 |
| Levacetylleucine (Aqneursa) (PDF) |
CP.PHAR.682 |
October 1, 2025 |
| Levodopa Inhalation Powder (Inbrija) (PDF) |
CP.PMN.267 |
January 1, 2025 |
| Levoketoconazole (Recorlev) (PDF) |
CP.PMN.275 |
October 1, 2025 |
| Levoleucovorin (Fusilev, Khapzory) (PDF) |
CP.PHAR.151 |
January 1, 2025 |
| Levomilnacipran (Fetzima) (PDF) |
HIM.PA.125 |
Version effective until December 1, 2025 |
| Levomilnacipran (Fetzima) (PDF) |
HIM.PA.125 |
December 1, 2025 |
| L-glutamine (Endari) (PDF) |
CP.PMN.116 |
January 1, 2025 |
| Lidocaine Transdermal (Lidoderm, ZTlido) (PDF) |
CP.PMN.08 |
October 1, 2025 |
| Lifileucel (Amtagvi) (PDF) |
CP.PHAR.598 |
January 1, 2025 |
| Lifitegrast (Xiidra®) (PDF) |
CP.PMN.73 |
April 1, 2025 |
| Linezolid (Zyvox) (PDF) |
CP.PMN.27 |
October 1, 2025 |
| Linvoseltamab-gcpt (Lynozyfic) (PDF) |
CP.PHAR.743 |
Version effective until November 1, 2025 |
| Linvoseltamab-gcpt (Lynozyfic) (PDF) |
CP.PHAR.743 |
November 1, 2025 |
| Lisocabtagene Maraleucel (Breyanzi) (PDF) |
CP.PHAR.483 |
July 1, 2025 |
| Lofexidine (Lucemyra) (PDF) |
CP.PMN.152 |
October 1, 2025 |
| Lomustine (Gleostine) (PDF) |
CP.PHAR.507 |
January 1, 2025 |
| Lonafarnib (Zokinvy) (PDF) |
CP.PHAR.499 |
April 1, 2025 |
| Loncastuximab Tesirine-lpyl (Zynlonta) (PDF) |
CP.PHAR.539 |
October 1, 2025 |
| Lorlatinib (Lorbrena)(PDF) |
CP.PHAR.406 |
Version effective until September 1, 2025 |
| Lorlatinib (Lorbrena)(PDF) |
CP.PHAR.406 |
September 1, 2025 |
| Loteprednol etabonate (Eysuvis) (PDF) |
CP.PMN.260 |
April 1, 2025 |
| Lotilaner (Xdemvy) (PDF) |
CP.PMN.291 |
January 1, 2025 |
| Lovotibeglogene Autotemcel (Lyfgenia) (PDF) |
CP.PHAR.627 |
June 1, 2025 |
| Lubiprostone (Amitiza) (PDF) |
CP.PMN.142 |
January 1, 2025 |
| Luliconazole Cream (Luzu) (PDF) |
CP.PMN.166 |
April 1, 2025 |
| Lumacaftor-Ivacaftor (Orkambi) (PDF) |
CP.PHAR.213 |
Version effective until December 1, 2025 |
| Lumacaftor-Ivacaftor (Orkambi) (PDF) |
CP.PHAR.213 |
December 1, 2025 |
| Lumasiran (Oxlumo) (PDF) |
CP.PHAR.473 |
April 1, 2025 |
| Lumateperone (Caplyta) (PDF) |
CP.PMN.232 |
October 1, 2025 |
| Lurbinectedin (Zepzelca) (PDF) |
CP.PHAR.500 |
October 1, 2025 |
| Luspatercept-aamt (Reblozyl) (PDF) |
CP.PHAR.450 |
April 1, 2025 |
| Lusutrombopag (Mulpleta)(PDF) |
CP.PHAR.407 |
April 1, 2025 |
| Lutetium Lu 177 dotatate (Lutathera) (PDF) |
CP.PHAR.384 |
October 1, 2025 |
| Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) (PDF) |
CP.PHAR.582 |
July 1, 2025 |
| Macitentan (Opsumit) (PDF) |
CP.PHAR.194 |
April 1, 2025 |
| Mannitol (Bronchitol) (PDF) |
CP.PHAR.518 |
October 1, 2025 |
| Maralixibat (Livmarli) (PDF) |
CP.PHAR.543 |
Version effective until December 1, 2025 |
| Maralixibat (Livmarli) (PDF) |
CP.PHAR.543 |
December 1, 2025 |
| Margetuximab-cmkb (Margenza) (PDF) |
CP.PHAR.522 |
April 1, 2025 |
| Maribavir (Livtencity) (PDF) |
CP.PMN.271 |
April 1, 2025 |
| Marstacimab-hncq (Hympavzi) (PDF) |
CP.PHAR.674 |
August 1, 2025 |
| Mavacamten (Camzyos) (PDF) |
CP.PMN.272 |
October 1, 2025 |
| Mavorixafor (Xolremdi) |
CP.PHAR.679 |
July 1, 2025 |
| Mecamylamine (Vecamyl) (PDF) |
CP.PMN.136 |
July 1, 2025 |
| Mecasermin (Increlex) (PDF) |
CP.PHAR.150 |
October 1, 2025 |
| Megestrol Acetate (PDF) |
CP.PMN.179 |
January 1, 2025 |
| Melphalan (Hepzato) (PDF) |
CP.PHAR.653 |
January 1, 2025 |
| Melphalan flufenamide (Pepaxto) (PDF) |
CP.PHAR.535 |
July 1, 2025 |
| Memantine (Namenda XR, Namzaric) (PDF) |
CP.PCH.30 |
October 1, 2025 |
| Mepolizumab (Nucala) (PDF) |
HIM.PA.175 |
October 1, 2025 |
| Mercaptopurine (Purixan) (PDF) |
CP.PHAR.447 |
Version effective until December 1, 2025 |
| Mercaptopurine (Purixan) (PDF) |
CP.PHAR.447 |
December 1, 2025 |
| Mechlorethamine (Valchlor) (PDF) |
CP.PHAR.381 |
October 1, 2025 |
| Metformin ER (Glumetza, Fortamet) (PDF) |
CP.PMN.72 |
April 1, 2025 |
| Methotrexate (Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo) (PDF) |
CP.PHAR.134 |
January 1, 2025 |
| Methoxsalen (Uvadex) (PDF) |
HIM.PA.17 |
January 1, 2025 |
| Methoxy polyethylene glycol-epoetin beta (Mircera) (PDF) |
CP.PHAR.238 |
Version effective until September 1, 2025 |
| Methoxy polyethylene glycol-epoetin beta (Mircera) (PDF) |
CP.PHAR.238 |
September 1, 2025 |
| Methylnaltrexone Bromide (Relistor) (PDF) |
CP.PMN.169 |
January 1, 2025 |
| Metoclopramide (Gimoti) (PDF) |
CP.PMN.252 |
January 1, 2025 |
| Metreleptin (Myalept) (PDF) |
CP.PHAR.425 |
October 1, 2025 |
| Midazolam (Nayzilam) (PDF) |
CP.PMN.211 |
October 1, 2025 |
| Midostaurin (Rydapt) (PDF) |
CP.PHAR.344 |
July 1, 2025 |
| Mifepristone (Korlym) (PDF) |
CP.PHAR.101 |
June 1, 2025 |
| Migalastat (Galafold) (PDF) |
CP.PHAR.394 |
July 1, 2025 |
| Miglustat (Zavesca) (PDF) |
CP.PHAR.164 |
September 1, 2025 |
| Milnacipran (Savella) (PDF) |
CP.PMN.125 |
Version effective until September 1, 2025 |
| Milnacipran (Savella) (PDF) |
CP.PMN.125 |
September 1, 2025 |
| Minocycline ER (Solodyn, Ximino, Minolira), Microspheres (Arestin), Foam (Zilxi) (PDF) |
CP.PMN.80 |
October 1, 2025 |
| Mirdametinib (Gomekli) (PDF) |
CP.PHAR.718 |
July 1, 2025 |
| Mirvetuximab soravatansine-gynx (Elahere) (PDF) |
CP.PHAR.617 |
April 1, 2025 |
| Mitapivat (Pyrukynd) (PDF) |
CP.PHAR.558 |
January 1, 2025 |
| Mitomycin for Pyelocalyceal Solution (Jelmyto) (PDF) |
CP.PHAR.495 |
Version effective until December 1, 2025 |
| Mitomycin for Pyelocalyceal Solution (Jelmyto) (PDF) |
CP.PHAR.495 |
December 1, 2025 |
| Mitoxantrone (PDF) |
CP.PHAR.258 |
July 1, 2025 |
| Mixed pollens allergen extract (Oralair) (PDF) |
CP.PMN.85 |
ctober 1, 2025 |
| Mobocertinib (Exkivity) (PDF) |
CP.PHAR.559 |
January 1, 2025 |
| Modafinil (Provigil) (PDF) |
CP.PMN.39 |
July 1, 2025 |
| Mogamulizumab-kpkc (Poteligeo) (PDF) |
CP.PHAR.139 |
March 1, 2025 |
| Momelotinib (Ojjaara) (PDF) |
CP.PHAR.654 |
January 1, 2025 |
| Mometasone (Nasonex) (PDF) |
HIM.PA.93 |
October 1, 2025 |
| Mometasone Furoate (Sinuva) (PDF) |
CP.PHAR.448 |
October 1, 2025 |
| Mosunetuzumab-axgb (Lunsumio) (PDF) |
CP.PHAR.618 |
April 1, 2025 |
| Motixafortide (Aphexda) (PDF) |
CP.PHAR.655 |
January 1, 2025 |
| Moxetumomab pasudotox-tdfk (Lumoxiti) (PDF) |
CP.PHAR.398 |
January 1, 2025 |
| Nabumatone Double-Strength (Relafen DS) (PDF) |
CP.PMN.287 |
October 1, 2025 |
| Nadofaragene Firadenovec-vncg (Adstiladrin) (PDF) |
CP.PHAR.461 |
March 1, 2025 |
| Nafarelin acetate (Synarel®) (PDF) |
CP.PHAR.174 |
July 1, 2025 |
| Naldemedine (Symproic) (PDF) |
CP.PMN.112 |
January 1, 2025 |
| Nalmefene (Opvee, Zurnai) (PDF) |
CP.PHAR.638 |
October 1, 2025 |
| Naloxegol (Movantik) (PDF) |
HIM.PA.167 |
January 1, 2025 |
| Naproxen/Esomeprazole (Vimovo) (PDF) |
CP.PMN.117 |
October 1, 2025 |
| Naproxen oral suspension (Naprosyn) (PDF) |
HIM.PA.130 |
January 1, 2025 |
| Natalizumab (Tysabri) (PDF) |
CP.PHAR.259 |
July 1, 2025 |
| Naxitamab-gqgk (Danyelza) (PDF) |
CP.PHAR.523 |
April 1, 2025 |
| Necitumumab (Portrazza) (PDF) |
CP.PHAR.320 |
January 1, 2025 |
| Nedosiran (Rivfloza) (PDF) |
CP.PHAR.619 |
Version effective until September 1, 2025 |
| Nedosiran (Rivfloza) (PDF) |
CP.PHAR.619 |
September 1, 2025 |
| Nemolizumab-ito (Nemluvio) (PDF) |
CP.PHAR.703 |
June 1, 2025 |
| Neomycin/Fluocinolone Cream (Neo-Synalar) (PDF) |
CP.PMN.167 |
January 1, 2025 |
| Neratinib (Nerlynx) (PDF) |
CP.PHAR.365 |
January 1, 2025 |
| Netupitant and Palonosetron (Akynzeo) (PDF) |
CP.PMN.158 |
October 1, 2025 |
| Nifurtimox (Lampit) (PDF) |
CP.PMN.256 |
January 1, 2025 |
| Nilotinib (Tasigna, Danziten) (PDF) |
CP.PHAR.76 |
July 1, 2025 |
| Nintedanib (Ofev) (PDF) |
CP.PCH.54 |
October 1, 2025 |
| Nipocalimab-aahu (Imaavy) (PDF) |
CP.PHAR.720 |
Version effective until November 1, 2025 |
| Nipocalimab-aahu (Imaavy) (PDF) |
CP.PHAR.720 |
November 1, 2025 |
| Niraparib (Zejula) (PDF) |
CP.PHAR.408 |
Version effective until December 1, 2025 |
| Niraparib (Zejula) (PDF) |
CP.PHAR.408 |
December 1, 2025 |
| Niraparib and Abiraterone (Akeega) (PDF) |
CP.PHAR.645 |
January 1, 2025 |
| Nirmatrelvir-Ritonavir (Paxlovid) (PDF) |
CP.PMN.288 |
October 1, 2025 |
| Nirogacestat (Ogsiveo) (PDF) |
CP.PHAR.671 |
April 1, 2025 |
| Nirsevimab-alip (Beyfortus) (PDF) |
CP.PHAR.614 |
October 1, 2025 |
| Nitazoxanide (Alinia) (PDF) |
HIM.PA.152 |
January 1, 2025 |
| Nitisinone (Nityr, Orfadin) (PDF) |
CP.PHAR.132 |
October 1, 2025 |
| Nivolumab, Nivolumab Hyaluronidase-nvhy (Opdivo, Opdivo Qvantig) (PDF) |
CP.PHAR.121 |
Version effective until December 1, 2025 |
| Nivolumab, Nivolumab Hyaluronidase-nvhy (Opdivo, Opdivo Qvantig) (PDF) |
CP.PHAR.121 |
December 1, 2025 |
| Nivolumab and Relatlimab-rmbw (Opdualag) (PDF) |
CP.PHAR.588 |
October 1, 2025 |
| No Coverage Criteria, Recent Label Changes Pending Clinical Policy Update (PDF) |
HIM.PA.33 |
January 1, 2025 |
| Nogapendekin alfa inbakicept-pmln (Anktiva) (PDF) |
CP.PHAR.684 |
October 1, 2025 |
| Non-Calcium Phosphate Binders (Auryxia, Fosrenol, Renagel, Renvela, Velphoro) (PDF) |
CP.PMN.04 |
June 1, 2024 |
| Non-Formulary and Formulary Contraceptives (PDF) |
HIM.PA.100 |
July 1, 2025 |
| Non-Formulary Test Strips (PDF) |
HIM.PA.34 |
April 1, 2025 |
| Nusinersen (Spinraza) (PDF) |
CP.PHAR.327 |
Verson effective until October 1, 2025 |
| Nusinersen (Spinraza) (PDF) |
CP.PHAR.327 |
October 1, 2025 |
| Obecabtagene autoleucel (Aucatzyl) (PDF) |
CP.PHAR.675 |
August 1, 2025 |
| Obeticholic acid (Ocaliva) (PDF) |
CP.PHAR.287 |
Verson effective until October 1, 2025 |
| Obeticholic acid (Ocaliva) (PDF) |
CP.PHAR.287 |
October 1, 2025 |
| Obinutuzumab (Gazyva) (PDF) |
CP.PHAR.305 |
January 1, 2025 |
| Ocrelizumab (Ocrevus) (PDF) |
CP.PHAR.335 |
October 1, 2025 |
| Octreotide Acetate (Sandostatin, Sandostatin LAR Depot, Bynfezia, Mycapssa) (PDF) |
CP.PHAR.40 |
June 1, 2025 |
| Odevixibat (Bylvay) (PDF) |
CP.PHAR.528 |
Version effective until November 1, 2025 |
| Odevixibat (Bylvay) (PDF) |
CP.PHAR.528 |
November 1, 2025 |
| Ofatumumab (Arzerra, Kesimpta) (PDF) |
CP.PHAR.306 |
October 1, 2025 |
| Off-Label Drug Use (PDF) |
HIM.PA.154 |
January 1, 2025 |
| Olanzapine Long-Acting Injection (Zyprexa Relprevv) (PDF) |
CP.PHAR.292 |
October 1, 2025 |
| Olanzapine-samidorphan (Lybalvi) (PDF) |
CP.PMN.265 |
October 1, 2025 |
| Olaparib (Lynparza) (PDF) |
CP.PHAR.360 |
April 1, 2025 |
| Olezarsen (Tryngolza) (PDF) |
CP.PHAR.689 |
October 1, 2025 |
| Olipudase Alfa-rpcp (Xenpozyme) (PDF) |
CP.PHAR.586 |
October 1, 2025 |
| Olutasidenib (Rezlidhia) (PDF) |
CP.PHAR.615 |
April 1, 2025 |
| Omacetaxine (Synribo) (PDF) |
CP.PHAR.108 |
Version effective until September 1, 2024 |
| Omacetaxine (Synribo) (PDF) |
CP.PHAR.108 |
September 1, 2025 |
| Omadacycline (Nuzyra) (PDF) |
CP.PMN.188 |
October 1, 2025 |
| Omalizumab (Xolair) (PDF) |
CP.PCH.49 |
Version effective until November 1, 2025 |
| Omalizumab (Xolair) (PDF) |
CP.PCH.49 |
November 1, 2025 |
| Omaveloxolone (Skyclarys) (PDF) |
CP.PHAR.590 |
July 1, 2025 |
| OnabotulinumtoxinA (Botox) (PDF) |
CP.PHAR.232 |
October 1, 2025 |
| Onasemnogene Abeparvovec (Zolgensma) (PDF) |
CP.PHAR.421 |
July 1, 2025 |
| Ophthalmic Corticosteroids (PDF) |
HIM.PA.03 |
January 1, 2025 |
| Ophthalmic Riboflavin (Photrexa, Photrexa Viscous) (PDF) |
CP.PHAR.536 |
July 1, 2025 |
| Opicapone (Ongentys) (PDF) |
CP.PMN.245 |
Version effective until October 2025 |
| Opicapone (Ongentys) (PDF) |
CP.PMN.245 |
October 2025 |
| Opioid Analgesics (PDF) |
HIM.PA.139 |
October 1, 2025 |
| Osilodrostat (Isturisa) (PDF) |
CP.PHAR.487 |
October 1, 2025 |
| Osimertinib (Tagrisso) (PDF) |
CP.PHAR.294 |
July 1, 2025 |
| Ospemifene (Osphena) (PDF) |
CP.PMN.168 |
January 1, 2025 |
| Overactive Bladder Agents (PDF) |
CP.PMN.198 |
September 1, 2025 |
| Oxymetazoline (Rhofade, Upneeq) (PDF) |
CP.PMN.86 |
October 1, 2025 |
| Ozanimod (Zeposia) (PDF) |
CP.PHAR.462 |
October 1, 2025 |
| Ozenoxacin (Xepi) (PDF) |
CP.PMN.119 |
October 1, 2025 |
| Paclitaxel, Protein-Bound (Abraxane) (PDF) |
CP.PHAR.176 |
October 1, 2025 |
| Pacritinib (Vonjo) (PDF) |
CP.PHAR.583 |
July 1, 2025 |
| Palbociclib (Ibrance) (PDF) |
HIM.PA.173 |
January 1, 2025 |
| Paliperidone Long-Acting Injections (Invega Hafyera, Invega Sustenna, Invega Trinza) (PDF) |
CP.PHAR.291 |
October 1, 2025 |
| Palivizumab (Synagis) (PDF) |
CP.PHAR.16 |
October 1, 2025 |
| Palopegteriparatide (Yorvipath) (PDF) |
CP.PHAR.696 |
January 1, 2025 |
| Palovarotene (PDF) |
CP.PHAR.548 |
October 1, 2025 |
| Pancrelipase (Creon, Pancreaze, Pertzye, Viokace, Zenpep) (PDF) |
CP.PCH.44 |
March 1, 2025 |
| Panitumumab (Vectibix) (PDF) |
CP.PHAR.321 |
May 1, 2025 |
| Parathyroid Hormone (Natpara) (PDF) |
CP.PHAR.282 |
April 1, 2025 |
| Paricalcitol Injection (Zemplar) (PDF) |
CP.PHAR.270 |
October 1, 2025 |
| Pasireotide (Signifor, Signifor LAR) (PDF) |
CP.PHAR.332 |
January 1, 2025 |
| Patiromer (Veltassa) (PDF) |
CP.PMN.205 |
October 1, 2025 |
| Patisiran (Onpattro) (PDF) |
CP.PHAR.395 |
July 1, 2025 |
| Pazopanib (Votrient) (PDF) |
CP.PHAR.81 |
Version effective until December 1, 2025 |
| Pazopanib (Votrient) (PDF) |
CP.PHAR.81 |
December 1, 2025 |
| Peanut allergen powder (Palforzia) (PDF) |
CP.PMN.220 |
October 1, 2025 |
| Pegaspargase (Oncaspar), Calaspargase Pegol-mknl (Asparlas) (PDF) |
CP.PHAR.353 |
March 1, 2025 |
| Pegcetacoplan (Empaveli, APL-2) (PDF) |
CP.PHAR.524 |
Version effective until December 1, 2025 |
| Pegcetacoplan (Empaveli, APL-2) (PDF) |
CP.PHAR.524 |
December 1, 2025 |
| Pegfilgrastim/Biosimilars, Eflapegrastim, Efbemalenograstim (PDF) |
CP.PHAR.296 |
October 1, 2025 |
| Peginterferon Alfa-2a (Pegasys) (PDF) |
CP.PHAR.89 |
Version erffective until December 1, 2025 |
| Peginterferon Alfa-2a (Pegasys) (PDF) |
CP.PHAR.89 |
December 1, 2025 |
| Peginterferon beta-1a (Plegridy) (PDF) |
CP.PHAR.271 |
July 1, 2025 |
| Pegloticase (Krystexxa) (PDF) |
CP.PHAR.115 |
April 1, 2025 |
| Pegunigalsidase Alfa-iwxj (Elfabrio) (PDF) |
CP.PHAR.512 |
Version effective until September 1, 2025 |
| Pegunigalsidase Alfa-iwxj (Elfabrio) (PDF) |
CP.PHAR.512 |
September 1, 2025 |
| Pegvaliase-pqpz (Palynziq) (PDF) |
CP.PHAR.140 |
March 1, 2025 |
| Pegvisomant (Somavert) (PDF) |
CP.PHAR.389 |
January 1, 2025 |
| Pembrolizumab (Keytruda®) (PDF) |
CP.PHAR.322 |
Version effective until December 1, 2025 |
| Pembrolizumab (Keytruda®) (PDF) |
CP.PHAR.322 |
December 1, 2025 |
| Pemetrexed (Alimta, Pemfexy, Axtle) (PDF) |
CP.PHAR.368 |
June 1, 2025 |
| Pemigatinib (Pemazyre) (PDF) |
CP.PHAR.496 |
Version effectice until December 1, 2025 |
| Pemigatinib (Pemazyre) (PDF) |
CP.PHAR.496 |
December 1, 2025 |
| Penicillamine (Cuprimine) (PDF) |
CP.PCH.09 |
January 1, 2025 |
| Penpulimab-kcqx (PDF) |
CP.PHAR.732 |
October 1, 2025 |
| Perampanel (Fycompa) (PDF) |
CP.PMN.156 |
October 1, 2025 |
| Perfluorohexyloctane (Miebo) (PDF) |
CP.PMN.290 |
October 1, 2025 |
| Pertuzumab (Perjeta) (PDF) |
CP.PHAR.227 |
Version effective until September 1, 2024 |
| Pertuzumab (Perjeta) (PDF) |
CP.PHAR.227 |
September 1, 2025 |
| Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (Phesgo) (PDF) |
CP.PHAR.501 |
October 1, 2025 |
| Pexidartinib (Turalio)(PDF) |
CP.PHAR.436 |
January 1, 2025 |
| Phendimetrazine (PDF) |
CP.PCH.47 |
July 1, 2025 |
| Phentermine (Adipex-P, Lomaira) (PDF) |
CP.PCH.13 |
July 1, 2025 |
| Pilocarpine (Vuity) (PDF) |
CP.PMN.270 |
January 1, 2025 |
| Pimavanserin (Nuplazid) (PDF) |
CP.PMN.140 |
October 1, 2025 |
| Pirfenidone (Esbriet) (PDF) |
CP.PHAR.286 |
October 1, 2025 |
| Pirtobrutinib (Jaypirca) (PDF) |
CP.PHAR.620 |
July 1, 2025 |
| Pitolisant (Wakix) (PDF) |
CP.PMN.221 |
October 1, 2025 |
| Plasminogen, human-tvmh (Ryplazim) (PDF) |
CP.PHAR.513 |
January1, 2025 |
| Plecanatide (Trulance) (PDF) |
CP.PMN.87 |
January 1, 2025 |
| Plerixafor (Mozobil) (PDF) |
CP.PHAR.323 |
October 1, 2025 |
| Polatuzumab Vedotin-piiq (Polivy) (PDF) |
CP.PHAR.433 |
Version effective until December 1, 2025 |
| Polatuzumab Vedotin-piiq (Polivy) (PDF) |
CP.PHAR.433 |
December 1, 2025 |
| Pomalidomide (Pomalyst) (PDF) |
CP.PHAR.116 |
July 1, 2025 |
| Ponatinib (Iclusig) (PDF) |
CP.PHAR.112 |
July 1, 2025 |
| Ponesimod (Ponvory) (PDF) |
CP.PHAR.537 |
October 1, 2025 |
| Potassium Chloride for Oral Solution (Klor-Con Powder) (PDF) |
HIM.PA.143 |
April 1, 2025 |
| Pozelimab-bbfg (Veopoz) (PDF) |
CP.PHAR.626 |
Version effective until September 1, 2025 |
| Pozelimab-bbfg (Veopoz) (PDF) |
CP.PHAR.626 |
September 1, 2025 |
| Prademagene Zamikeracel (Zevaskyn) (PDF) |
CP.PHAR.609 |
October 1, 2025 |
| Pralatrexate (Folotyn) (PDF) |
CP.PHAR.313 |
March 1, 2025 |
| Pramlintide (Symlin) (PDF) |
CP.PMN.129 |
April 1, 2025 |
| Prasterone (Intrarosa) (PDF) |
CP.PMN.99 |
April 1, 2025 |
| Pregabalin (Lyrica) (PDF) |
CP.PMN.33 |
July 1, 2025 |
| Pretomanid (PDF) |
CP.PMN.222 |
April 1, 2025 |
| Progesterone (Crinone, Endometrin, Milprosa) (PDF) |
CP.PMN.243 |
October 1, 2025 |
| Propranolol (Hemangeol) (PDF) |
CP.PCH.51 |
July 1, 2025 |
| Protein C Concentrate, Human (Ceprotin) (PDF) |
CP.PHAR.330 |
April 1, 2025 |
| Prucalopride (Motegrity) (PDF) |
HIM.PA.159 |
September 1, 2025 |
| Pyrimethamine (Daraprim®) (PDF) |
CP.PMN.44 |
Version effective until December 1, 2025 |
| Pyrimethamine (Daraprim®) (PDF) |
CP.PMN.44 |
December 1, 2025 |
| Quantity Limit Override and Dose Optimization (PDF) |
CP.PMN.59 |
January 1, 2025 |
| Quetiapine ER (Seroquel XR) (PDF) |
CP.PMN.64 |
April 1, 2025 |
| Quinine Sulfate (Qualaquin) (PDF) |
CP.PMN.262 |
October 1, 2025 |
| Quizartinib (Vanflyta) (PDF) |
CP.PHAR.646 |
January 1, 2025 |
| Ramucirumab (Cyramza) (PDF) |
CP.PHAR.119 |
July 1, 2025 |
| Ranibizumab (Lucentis, Susvimo), Lucentis Biosimilars (PDF) |
CP.PHAR.186 |
August 1, 2025 |
| Rasagiline (Azilect®) (PDF) |
HIM.PA.89 |
October 1, 2025 |
| Ravulizumab-cwvz (Ultomiris) (PDF) |
CP.PHAR.415 |
Version effective until December 1, 2025 |
| Ravulizumab-cwvz (Ultomiris) (PDF) |
CP.PHAR.415 |
December 1, 2025 |
| Regorafenib (Stivarga) (PDF) |
CP.PHAR.107 |
July 1, 2025 |
| Relugolix (Orgovyx), Relugolix/Estradiol/Norethinedrone (Myfembree) (PDF) |
CP.PHAR.529 |
October 1, 2025 |
| Remestemcel-L (Ryoncil) (PDF) |
CP.PHAR.474 |
Version effective until November 1, 2025 |
| Remestemcel-L (Ryoncil) (PDF) |
CP.PHAR.474 |
November 1, 2025 |
| Remetirom (Rezdiffra) (PDF) |
CP.PHAR.647 |
January 1, 2025 |
| Repository Corticotropin Injection (H.P. Acthar Gel, Purified Cortrophin Gel) (PDF) |
HIM.PA.168 |
October 1, 2025 |
| Repotrectinib (Augtyro) (PDF) |
CP.PHAR.667 |
April 1, 2025 |
| Reslizumab (Cinqair) (PDF) |
CP.PHAR.223 |
April 1, 2025 |
| Respiratory syncytial virus vaccine (Abrysvo) (PDF) |
CP.PHAR.658 |
January 1, 2025 |
| Retifanlimab-dlwr (Zynyz) (PDF) |
CP.PHAR.629 |
Version effective until July 1, 2025 |
| Retifanlimab-dlwr (Zynyz) (PDF) |
CP.PHAR.629 |
August 1, 2025 |
| Revakinagene Taroretcel-lwey (Encelto) (PDF) |
CP.PHAR.697 |
July 1, 2025 |
| Revumenib (Revuforj) (PDF) |
CP.PHAR.707 |
April 1, 2025 |
| Ribavirin (Copegus, Moderiba, Rebetol, Ribasphere) (PDF) |
CP.PHAR.141 |
January 1, 2025 |
| Ribociclib (Kisqali, Kisqali Femara) (PDF) |
CP.PHAR.334 |
March 1, 2025 |
| Rifabutin (Mycobutin) (PDF) |
CP.PMN.223 |
April 1, 2025 |
| Rifamycin (Aemcolo) (PDF) |
CP.PMN.196 |
October 1, 2025 |
| Rifaximin (Xifaxan®) (PDF) |
CP.PMN.47 |
January 1, 2025 |
| Rilonacept (Arcalyst) (PDF) |
CP.PHAR.266 |
Version effective until September 1, 2025 |
| Rilonacept (Arcalyst) (PDF) |
CP.PHAR.266 |
September 1, 2025 |
| RimabotulinumtoxinB (Myobloc) (PDF) |
CP.PHAR.233 |
October 1, 2025 |
| Rimegepant (Nurtec ODT) (PDF) |
CP.PHAR.490 |
January 1, 2025 |
| Riociguat (Adempas®) (PDF) |
CP.PHAR.195 |
April 1, 2025 |
| Ripretinib (Qinlock) (PDF) |
CP.PHAR.502 |
October 1, 2025 |
| Risdiplam (Evrysdi) (PDF) |
CP.PHAR.477 |
July 1, 2025 |
| Risedronate (Actonel, Atelvia) (PDF) |
CP.PMN.100 |
June 1, 2025 |
| Risperidone Long-Acting Injection (Perseris, Risperdal Consta, Rykindo, Uzedy) (PDF) |
CP.PHAR.293 |
October 1, 2025 |
| Rituximab (Rituxan, Riabni, Ruxience, Truxima, Rituxan Hycela) (PDF) |
CP.PHAR.260 |
October 1, 2025 |
| Roflumilast (Daliresp, Zoryve) (PDF) |
CP.PMN.46 |
October 1, 2025 |
| Rolapitant (Varubi) (PDF) |
CP.PMN.102 |
October 1, 2025 |
| Romidepsin (Istodax) (PDF) |
CP.PHAR.314 |
January1, 2025 |
| Romiplostim (Nplate) (PDF) |
CP.PHAR.179 |
April 1, 2025 |
| Romosozumab-aqqg (Evenity) (PDF) |
CP.PHAR.428 |
Version effective until December 1, 2025 |
| Romosozumab-aqqg (Evenity) (PDF) |
CP.PHAR.428 |
December 1, 2025 |
| Ropeginterferon Alfa-2b-njft (BESREMi) (PDF) |
CP.PHAR.570 |
April 1, 2025 |
| Rozanolixizumab-noli (Rystiggo) (PDF) |
CP.PHAR.648 |
March 1, 2025 |
| Rucaparib (Rubraca®) (PDF) |
CP.PHAR.350 |
April 1, 2025 |
| Rufinamide (Banzel) (PDF) |
CP.PMN.157 |
Version effective until December 1, 2025 |
| Rufinamide (Banzel) (PDF) |
CP.PMN.157 |
December 1, 2025 |
| Ruxolitinib (Jakafi) (PDF) |
CP.PHAR.98 |
April 1, 2025 |
| Sacituzumab Govitecan-hziy (Trodelvy) (PDF) |
CP.PHAR.475 |
July 1, 2025 |
| Sacubitril/Valsartan (Entresto) (PDF) |
CP.PCH.52 |
April 1, 2025 |
| Safinamide (Xadago) (PDF) |
CP.PMN.113 |
April 1, 2025 |
| Sapropterin Dihydrochloride (Kuvan, Javygtor) (PDF) |
CP.PHAR.43 |
Version effective until September 1, 2025 |
| Sapropterin Dihydrochloride (Kuvan, Javygtor) (PDF) |
CP.PHAR.43 |
September 1, 2025 |
| Sarecycline (Seysara) (PDF) |
CP.PMN.189 |
April 1, 2025 |
| Sargramostim (Leukine) (PDF) |
CP.PHAR.295 |
Version effective until December 1, 2025 |
| Sargramostim (Leukine) (PDF) |
CP.PHAR.295 |
December 1, 2025 |
| Satralizumab-mwge (Enspryng) (PDF) |
CP.PHAR.463 |
Version effective until December 1, 2025 |
| Satralizumab-mwge (Enspryng) (PDF) |
CP.PHAR.463 |
December 1, 2025 |
| Sebelipase Alfa (Kanuma) (PDF) |
CP.PHAR.159 |
July 1, 2025 |
| Sebetralstat (Ekterly) (PDF) |
CP.PHAR.723 |
Version effective until November 1, 2025 |
| Sebetralstat (Ekterly) (PDF) |
CP.PHAR.723 |
November 1, 2025 |
| Secnidazole (Solosec) (PDF) |
CP.PMN.103 |
April 1, 2025 |
| Seladelpar (Livdelzi) (PDF) |
CP.PHAR.698 |
January 1, 2025 |
| Selexipag (Uptravi®) (PDF) |
CP.PHAR.196 |
April 1, 2025 |
| Selinexor (Xpovio) (PDF) |
CP.PHAR.431 |
October 1, 2025 |
| Selpercatinib (Retevmo) (PDF) |
CP.PHAR.478 |
July 1, 2025 |
| Selumetinib (Koselugo) (PDF) |
CP.PHAR.464 |
June 1, 2025 |
| Semaglutide (Wegovy) (PDF) |
CP.PMN.295 |
October 1, 2025 |
| Semaglutide (Wegovy) - FEHB Members Only (PDF) |
QR.QC.CP.352 |
January 1, 2025 |
| Sepiapterin (Sephience) |
CP.PHAR.708 |
November 1, 2025 |
| Sepsis Diagnosis (PDF) |
CC.PP.073 |
November 1, 2024 |
| Setmelanotide (Imcivree) (PDF) |
CP.PHAR.491 |
July 1, 2025 |
| Short ragweed pollen allergen extract (Ragwitek) (PDF) |
CP.PMN.83 |
October 1, 2025 |
| Sildenafil (Revatio®) (PDF) |
CP.PHAR.197 |
April 1, 2025 |
| Sildenafil (Viagra) (PDF) |
CP.PCH.07 |
July 1, 2025 |
| Siltuximab (Sylvant) (PDF) |
CP.PHAR.329 |
April 1, 2025 |
| Siponimod (Mayzent) (PDF) |
CP.PHAR.427 |
October 1, 2025 |
| Sirolimus Protein-Bound Particles (Fyarro), Topical Gel (Hyftor) (PDF) |
CP.PHAR.574 |
April 1, 2025 |
| Sodium Oxybate (Xyrem, Lumryz) and Calcium Magnesium Potassium Sodium Oxybate (Xywav) (PDF) |
CP.PMN.42 |
October 1, 2025 |
| Sodium Phenylbutyrate (Buphenyl) (PDF) |
CP.PHAR.208 |
April 1, 2025 |
| Sodium Phenylbutyrate-Taurursodiol (Relyvrio) (PDF) |
CP.PHAR.584 |
July 1, 2025 |
| Sodium thiosulfate (Pedmark) (PDF) |
CP.PHAR.610 |
April 1, 2025 |
| Sodium Zirconium Cyclosilicate (Lokelma) (PDF) |
CP.PMN.163 |
October 1, 2025 |
| Sodium-Glucose Co-Transporter 2 Inhibitors (PDF) |
HIM.PA.91 |
April 1, 2025 |
| Sofosbuvir (Sovaldi) (PDF) |
HIM.PA.SP2 |
Version effective until December 1, 2025 |
| Sofosbuvir (Sovaldi) (PDF) |
HIM.PA.SP2 |
December 1, 2025 |
| Sofosbuvir-Vepatasvir-Voxilaprevir (Vosevi) (PDF) |
HIM.PA.SP63 |
Version effective until December 1, 2025 |
| Sofosbuvir-Vepatasvir-Voxilaprevir (Vosevi) (PDF) |
HIM.PA.SP63 |
December 1, 2025 |
| Solriamfetol (Sunosi) (PDF) |
CP.PMN.209 |
Version effective until September 1, 2025 |
| Solriamfetol (Sunosi) (PDF) |
CP.PMN.209 |
September 1, 2025 |
| Sonidegib (Odomzo) (PDF) |
CP.PHAR.272 |
July 1, 2025 |
| Sorafenib (Nexavar) (PDF) |
CP.PHAR.69 |
Version effective until September 1, 2025 |
| Sorafenib (Nexavar) (PDF) |
CP.PHAR.69 |
September 1, 2025 |
| Sotatercept (ACE-011) (PDF) |
CP.PHAR.657 |
April 1, 2025 |
| Sotorasib (Lumakras) (PDF) |
CP.PHAR.549 |
October 1, 2025 |
| Sparsentan (Filspari) (PDF) |
CP.PHAR.631 |
October 1, 2025 |
| Spesolimab-sbzo (Spevigo) (PDF) |
CP.PHAR.606 |
October 1, 2025 |
| Spinosad (Natroba) (PDF) |
HIM.PA.134 |
October 1, 2025 |
| Step Therapy Criteria (PDF) |
HIM.PA.109 |
July 1, 2025 |
| Stiripentol (Diacomit) (PDF) |
CP.PMN.184 |
January 1, 2025 |
| Sunitinib (Sutent) (PDF) |
CP.PHAR.73 |
Version effective until September 1, 2025 |
| Sunitinib (Sutent) (PDF) |
CP.PHAR.73 |
September 1, 2025 |
| Sunvozertinib (Zegfrovy) (PDF) |
CP.PHAR.742 |
October 1, 2025 |
| Sutimlimab-jome (Enjaymo) (PDF) |
CP.PHAR.503 |
July 1, 2025 |
| Suvorexant (Belsomra®) (PDF) |
CP.PMN.109 |
January 1, 2025 |
| Suzetrigine (Journavx) (PDF) |
CP.PMN.301 |
October 1, 2025 |
| Tadalafil (Adcirca®) (PDF) |
CP.PHAR.198 |
April 1, 2025 |
| Tadalafil BHP - ED (Cialis) (PDF) |
CP.PMN.132 |
October 1, 2025 |
| Tafamidis (Vyndaqel, Vyndamax) (PDF) |
CP.PHAR.432 |
October 1, 2025 |
| Tafasitamab-cxix (Monjuvi) (PDF) |
CP.PHAR.508 |
October 1, 2025 |
| Talazoparib (Talzenna)(PDF) |
CP.PHAR.409 |
April 1, 2025 |
| Taletrectinib (Ibtrozi) (PDF) |
CP.PHAR.740 |
October 1, 2025 |
| Taliglucerase Alfa (Elelyso) (PDF) |
CP.PHAR.157 |
October 1, 2025 |
| Talimogene laherepvec (Imlygic) (PDF) |
CP.PHAR.542 |
October 1, 2025 |
| Talquetamab-tgvs (Talvey) (PDF) |
CP.PHAR.649 |
March 1, 2025 |
| Tapinarof (Vtama) (PDF) |
CP.PMN.283 |
April 1, 2025 |
| Tarlatamab-dlle (Imdelltra) (PDF) |
CP.PHAR.685 |
October 1, 2025 |
| Tasimelteon (Hetlioz) (PDF) |
CP.PMN.104 |
April 1, 2025 |
| Tavaborole (Kerydin®) (PDF) |
CP.PMN.105 |
April 1, 2025 |
| Tazarotene (Arazlo, Fabior, Tazorac) (PDF) |
CP.PMN.244 |
January 1, 2025 |
| Tazemetostat (PDF) |
CP.PHAR.452 |
April 1, 2025 |
| Tebentafusp-tebn (Kimmtrak) (PDF) |
CP.PHAR.575 |
July 1, 2025 |
| Teclistamab-cqyv (Tecvayli) (PDF) |
CP.PHAR.611 |
April 1, 2025 |
| Tedizolid (Sivextro) (PDF) |
CP.PMN.62 |
October 1, 2025 |
| Teduglutide (Gattex) (PDF) |
CP.PHAR.114 |
April 1, 2025 |
| Telisotuzumab Vedotin-tllv (Emrelis) (PDF) |
CP.PHAR.733 |
Version effective until November 1, 2025 |
| Telisotuzumab Vedotin-tllv (Emrelis) (PDF) |
CP.PHAR.733 |
November 1, 2025 |
| Telotristat Ethyl (Xermelo) (PDF) |
CP.PHAR.337 |
October 1, 2025 |
| Temozolomide (Temodar) (PDF) |
CP.PHAR.77 |
Version effective until September 1, 2025 |
| Temozolomide (Temodar) (PDF) |
CP.PHAR.77 |
September 1, 2025 |
| Temsirolimus (Torisel) (PDF) |
CP.PHAR.324 |
January 1, 2025 |
| Tenapanor (Ibsrela, Xphozah) (PDF) |
CP.PMN.224 |
October 1, 2025 |
| Tenapanor (Ibsrela, Xphozah) (PDF) |
HIM.PA.174 |
July 1, 2025 |
| Tenofovir Alafenamide Fumarate (Vemlidy) (PDF) |
CP.PMN.268 |
October 1, 2025 |
| Teplizumab-mzwv (Tzield) (PDF) |
CP.PHAR.492 |
April 1, 2025 |
| Tepotinib (Tepmetko) (PDF) |
CP.PHAR.530 |
July 1, 2025 |
| Teprotumumab (Tepezza) (PDF) |
CP.PHAR.465 |
April 1, 2025 |
| Teriflunomide (Aubagio) (PDF) |
CP.PCH.40 |
July 1, 2025 |
| Teriparatide (Forteo®) (PDF) |
CP.PHAR.188 |
October 1, 2025 |
| Tesamorelin (Egrifta) (PDF) |
CP.PHAR.109 |
October 1, 2025 |
| Testosterone (Androderm) (PDF) |
HIM.PA.87 |
June 1, 2025 |
| Testosterone (Testopel, Jatenzo, Kyzatrex, Tlando) (PDF) |
CP.PHAR.354 |
June 1, 2025 |
| Tetrabenazine (Xenazine) (PDF) |
CP.PHAR.92 |
July 1, 2025 |
| Tezacaftor-Ivacaftor (Symdeko) (PDF) |
CP.PHAR.377 |
Version effective until December 1, 2025 |
| Tezacaftor-Ivacaftor (Symdeko) (PDF) |
CP.PHAR.377 |
December 1, 2025 |
| Tezepelumab-ekko (Tezspire) (PDF) |
CP.PHAR.576 |
May 1, 2024 |
| Thalidomide (Thalomid) (PDF) |
CP.PHAR.78 |
October 1, 2025 |
| Thioguanine (Tabloid) (PDF) |
CP.PHAR.437 |
January 1, 2025 |
| Thyrotropin alfa (Thyrogen) (PDF) |
CP.PHAR.95 |
October 1, 2025 |
| Timothy grass pollen allergen extract (Grastek®) (PDF) |
CP.PMN.84 |
October 1, 2025 |
| Tiopronin Delayed-Release (Thiola EC) (PDF) |
CP.PCH.50 |
July 1, 2025 |
| Tiopronin Delayed-Release (Thiola EC) (PDF) |
CP.PHAR.725 |
July 1, 2025 |
| Tirzepatide (Zepbound) (PDF) |
CP.PMN.298 |
October 1, 2025 |
| Tisagenlecleucel (Kymriah) (PDF) |
CP.PHAR.361 |
June 1, 2025 |
| Tislelizumab-jsgr (Tevimbra) (PDF) |
CP.PHAR.687 |
October 1, 2025 |
| Tisotumab Vedotin-tftv (Tivdak) (PDF) |
CP.PHAR.561 |
March 1, 2025 |
| Tivozanib (Fotivda) (PDF) |
CP.PHAR.538 |
July 1, 2025 |
| Tobramycin (PDF) |
CP.PHAR.211 |
October 1, 2025 |
| Tofersen (Qalsody) (PDF) |
CP.PHAR.591 |
January1, 2025 |
| Tolvaptan (Jynarque) (PDF) |
CP.PHAR.27 |
Version effective until December 1, 2025 |
| Tolvaptan (Jynarque) (PDF) |
CP.PHAR.27 |
December 1, 2025 |
| Topical Acne Treatment (PDF) |
HIM.PA.71 |
January 1, 2025 |
| Topical Immunomodulators (PDF) |
CP.PMN.107 |
April 1, 2025 |
| Topiramate ER (Qudexy XR, Trokendi XR (PDF) |
CP.PMN.281 |
Version effective until December 1, 2025 |
| Topiramate ER (Qudexy XR, Trokendi XR (PDF) |
CP.PMN.281 |
December 1, 2025 |
| Topotecan (Hycamtin) (PDF) |
CP.PHAR.64 |
July 1, 2025 |
| Toripalimab (Loqtorzi) (PDF) |
CP.PHAR.668 |
April 1, 2025 |
| Tovorafenib (Ojemda) (PDF) |
CP.PHAR.686 |
October 1, 2025 |
| Trabectedin (Yondelis) (PDF) |
CP.PHAR.204 |
April 1, 2025 |
| Tralokinumab-ldrm (Adbry) (PDF) |
CP.PHAR.577 |
July 1, 2025 |
| Trametinib (Mekinist) (PDF) |
CP.PHAR.240 |
July 1, 2025 |
| Trastuzumab/Biosimilars, Trastuzumab-Hyaluronidase (PDF) |
CP.PHAR.228 |
Version effective until July 1, 2025 |
| Trastuzumab/Biosimilars, Trastuzumab-Hyaluronidase (PDF) |
CP.PHAR.228 |
August 1, 2025 |
| Travoprost (iDose TR) (PDF) |
CP.PHAR.672 |
April 1, 2025 |
| Tremelimumab-actl (Imjudo) (PDF) |
CP.PHAR.612 |
June 1, 2025 |
| Treprostinil (Orenitram®, Remodulin®, Tyvaso®) (PDF) |
CP.PHAR.199 |
Version effective until November 1, 2025 |
| Treprostinil (Orenitram®, Remodulin®, Tyvaso®) (PDF) |
CP.PHAR.199 |
November 1, 2025 |
| Triamcinolone ER Injection (Zilretta) (PDF) |
CP.PHAR.371 |
June 1, 2025 |
| Triclabendazole (Egaten) (PDF) |
CP.PMN.207 |
October 1, 2025 |
| Trientine (Syprine) (PDF) |
CP.PHAR.438 |
January 1, 2025 |
| Trifarotene (Aklief) (PDF) |
CP.PMN.225 |
April 1, 2025 |
| Trifluridine/Tipiracil (Lonsurf) (PDF) |
CP.PHAR.383 |
October 1, 2025 |
| Triheptanoin (Dojolvi) (PDF) |
CP.PHAR.509 |
January 1, 2025 |
| Triptorelin Pamoate (Trelstar, Triptodur) (PDF) |
CP.PHAR.175 |
June 1, 2025 |
| Trofinetide (Daybue) (PDF) |
CP.PHAR.600 |
July 1, 2025 |
| Tucatinib (Tukysa) (PDF) |
CP.PHAR.497 |
October 1, 2025 |
| Ublituximab-xiiy (Briumvi) (PDF) |
CP.PHAR.621 |
October 1, 2025 |
| Ulcer Therapy Products (Omeclamox Pak, Pylera, Talicia, Voquezna) (PDF) |
CP.PMN.277 |
October 1, 2025 |
| Umbralisib (Ukoniq) (PDF) |
CP.PHAR.531 |
July 1, 2025 |
| Uridine acetate (Vistogard) (PDF) |
HIM.PA.SP55 |
January 1, 2025 |
| Vadadustat (Vafseo) (PDF) |
CP.PHAR.677 |
Version effective until September 1, 2025 |
| Vadadustat (Vafseo) (PDF) |
CP.PHAR.677 |
September 1, 2025 |
| Valbenazine (Ingrezza) (PDF) |
CP.PCH.48 |
July 1, 2025 |
| Valganciclovir (Valcyte) (PDF) |
CP.PCH.06 |
April 1, 2025 |
| Valoctocogene Roxaparvovec-rvox (Roctavian) (PDF) |
CP.PHAR.466 |
May 1, 2025 |
| Valrubicin (Valstar) (PDF) |
CP.PHAR.439 |
March 1, 2025 |
| Vamorolone (Agamree) (PDF) |
CP.PHAR.659 |
April 1, 2025 |
| Vandetanib (Caprelsa®) (PDF) |
CP.PHAR.80 |
April 1, 2025 |
| Vanzacaftor/Tezacaftor/Deutivacaftor (Alyftrek) (PDF) |
CP.PHAR.700 |
October 1, 2025 |
| Varenicline (Tyrvaya) (PDF) |
CP.PMN.273 |
April 1, 2025 |
| Velaglucerase Alfa (VPRIV) (PDF) |
CP.PHAR.163 |
October 1, 2025 |
| Velmanase Alfa-tycv (Lamzede) (PDF) |
CP.PHAR.601 |
July 1, 2025 |
| Velpatasvir (Epclusa) (PDF) |
HIM.PA.SP1 |
Version effective until December 1, 2025 |
| Velpatasvir (Epclusa) (PDF) |
HIM.PA.SP1 |
December 1, 2025 |
| Vemurafenib (Zelboraf®) (PDF) |
CP.PHAR.91 |
June 1, 2025 |
| Venetoclax (Venclexta) (PDF) |
CP.PHAR.129 |
January 1, 2025 |
| Verteporfin (Visudyne) (PDF) |
CP.PHAR.187 |
April 1, 2025 |
| Vestronidase Alfa-vjbk (Mepsevii) (PDF) |
CP.PHAR.374 |
July 1, 2025 |
| Vigabatrin (Sabril) (PDF) |
CP.PHAR.169 |
Version effective until December 1, 2025 |
| Vigabatrin (Sabril) (PDF) |
CP.PHAR.169 |
December 1, 2025 |
| Viloxazine (Qelbree) (PDF) |
CP.PMN.264 |
Version effective until November 1, 2025 |
| Viloxazine (Qelbree) (PDF) |
CP.PMN.264 |
November 1, 2025 |
| Viltolarsen (Viltepso) (PDF) |
CP.PHAR.484 |
April 1, 2025 |
| Vimseltinib (Romvimza) (PDF) |
CP.PHAR.726 |
July 1, 2025 |
| Vismodegib (Erivedge) (PDF) |
CP.PHAR.273 |
July 1, 2025 |
| Voclosporin (Lupkynis) (PDF) |
CP.PHAR.504 |
July 1, 2025 |
| Vorapaxar (Zontivity) (PDF) |
HIM.PA.146 |
April 1, 2025 |
| Vorasidenib (Voranigo) (PDF) |
CP.PHAR.699 |
January 1, 2025 |
| Voretigene Neparvovec-rzyl (Luxturna) (PDF) |
CP.PHAR.372 |
April 1, 2025 |
| Vorinostat (Zolinza) (PDF) |
CP.PHAR.83 |
October 1, 2025 |
| Vortioxetine (Trintellix®) (PDF) |
CP.PMN.65 |
Version effective until December 1, 2025 |
| Vortioxetine (Trintellix®) (PDF) |
CP.PMN.65 |
December 1, 2025 |
| Vosoritide (Voxzogo) (PDF) |
CP.PHAR.525 |
April 1, 2025 |
| Voxelotor (Oxbryta) (PDF) |
CP.PHAR.451 |
April 1, 2025 |
| Vutrisiran (Amvuttra) |
CP.PHAR.550 |
July 1, 2025 |
| Xanomeline-trospium chloride (Cobenfy) |
CP.PMN.299 |
April 1, 2025 |
| Zanidatamab-hrii (Ziihera) (PDF) |
CP.PHAR.709 |
August 1, 2025 |
| Zanubrutinib (Brukinsa) (PDF) |
CP.PHAR.467 |
October 1, 2025 |
| Zavegepant (Zavzpret) (PDF) |
CP.PHAR.630 |
March 1, 2025 |
| Zenocutuzumab-zbco (Bizengri) (PDF) |
CP.PHAR.713 |
August 1, 2025 |
| Zilucoplan (RA101495) (PDF) |
CP.PHAR.616 |
June 1, 2025 |
| Ziv-aflibercept (Zaltrap) (PDF) |
CP.PHAR.325 |
January 1, 2025 |
| Zolbetuximab-clzb (Vyloy) (PDF) |
CP.PHAR.705 |
Version effective until July 1, 2025 |
| Zolbetuximab-clzb (Vyloy) (PDF) |
CP.PHAR.705 |
August 1, 2025 |
| Zoledronic Acid (Reclast) (PDF) |
CP.PHAR.59 |
June 1, 2025 |
| Zuranolone (Zurzuvae) (PDF) |
CP.PHAR.650 |
July 1, 2025 |